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ABSTRACT 
 
Introduction. Monocytes are cells of the innate immunity system with high heterogeneity and 
plasticity and are involved in acute and chronic inflammatory states. Monocytes are traditionally 
distinguished in three subsets, based on CD14 (LPS co-receptor) and CD16 (FcγIII receptor with 
low IgG affinity) expression: classical, intermediate and non-classical. Monocyte subsets have a 
developmental relationship and differ in phenotypic and functional characteristics. Distribution of 
monocyte subsets has been shown to predict cardiovascular outcomes. Nevertheless, monocytes 
have now been redefined as a continuum of subsets with dynamic changes of their characteristics 
and classification into different subtypes may be an oversimplification. Monocytes have been 
studied in cardiovascular diseases because they are involved in inflammatory processes linked with 
these pathological states: they have a central role in the development of atherosclerotic plaques, that 
represent the major cause of cardiovascular events. Changes within different monocyte subsets are 
reported in several studies in relation with cardiovascular risk factors and cardiovascular diseases. 
Aim of the study. The aim of this study is to establish whether distribution of monocytes based on 
CD14 and CD16 fluorescence intensity provides incremental and complementary information in 
relation to cardiovascular risk factors, prevalent cardiovascular diseases and cardiovascular 
outcomes beyond enumeration of traditional subsets. 
Materials and methods. A cohort of 227 patients with high cardiovascular risk (patients with at 
least two classical cardiovascular risk factors or with establish cardiovascular disease) were 
recruited for this study and followed up for a median of 4 years. Monocyte subsets were quantified 
and characterized at baseline using polychromatic flow cytometry, based on the CD14 e CD16 
expression; for each monocyte subset frequency and mean fluorescence intensity (MFI) of CD14 
and CD16 were determined, evaluating the continuous distribution. These monocyte characteristics 
were studied in patients in relation to cardiovascular risk factors, prevalence of coronary artery 
disease (CAD) and occurrence of major adverse cardiovascular events (MACE) during follow-up. 
Results. In relation to cardiovascular risk factors, every monocyte subset of patients with type 2 
diabetes showed a consistent shift toward higher CD16 fluorescence intensity, despite no changes in 
their frequencies. Patients with coronary artery disease (CAD) at baseline displayed a doubled 
amount of CD14++ CD16+, intermediate monocytes, and a shift of non-classical and classical 
monocytes towards intermediates ones. During follow-up, cardiovascular death or cardiovascular 
events occurred in 26 patients, who showed monocyte displacement similar to those of patients with 
CAD at baseline. Using a Cox proportional hazard regression models, among monocytes 
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parameters, only the higher CD16 expression on classical monocytes, independently predicted 
adverse cardiovascular outcomes, but not the level of intermediate monocytes or other subsets. 
Discussion and conclusion. Changes within monocyte subsets in patients with CAD and in patients 
with incident MACE during follow-up suggested a shift of classical and non-classical monocytes 
towards intermediate monocytes, showing phenotypic changes within the monocyte continuum. The 
predictive role of CD16 MFI on classical monocytes highlights how the concept of monocyte 
continuum can be used to shape the cardiovascular risk more than frequencies of monocyte subsets 
can do. 
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RIASSUNTO 
 
Introduzione. I monociti sono cellule del sistema dell’immunità innata con elevata eterogeneità e 
plasticità e sono coinvolti in stati infiammatori acuti e cronici. I monociti sono tradizionalmente 
distinti in tre sottopopolazioni, in base all'espressione del CD14 (co-recettore dell’LPS) e CD16 
(recettore FcγIII con bassa affinità per IgG): classici, intermedi e non classici. Questi sottogruppi 
monocitari hanno una relazione evolutiva e differiscono per caratteristiche fenotipiche e funzionali. 
La distribuzione dei sottoinsiemi monocitari ha dimostrato di prevedere gli esiti cardiovascolari. 
Tuttavia, i monociti sono recentemente stati ridefiniti come un continuum di sottoinsiemi con 
cambiamenti dinamici delle loro caratteristiche e la categorizzazione in sottoinsiemi discreti può 
essere considerata come un’eccessiva semplificazione. Nelle malattie cardiovascolari i monociti 
sono stati studiati in quanto coinvolti in processi infiammatori legati a questi stati patologici: hanno 
un ruolo centrale nello sviluppo delle placche aterosclerotiche, che rappresentano la principale 
causa per gli eventi cardiovascolari. Diversi studi hanno dimostrato cambiamenti all'interno dei 
sottoinsiemi monocitari in relazione ai tradizionali fattori di rischio cardiovascolare e alle patologie 
cardiovascolari. 
Scopo dello studio. Lo scopo di questo studio è stabilire se la distribuzione dei monociti basata 
sull'intensità di fluorescenza del CD14 e del CD16 fornisce informazioni incrementali e 
complementari in relazione ai fattori di rischio cardiovascolare, alle patologie cardiovascolari 
prevalenti e agli esiti cardiovascolari rispetto alla quantificazione della frequenza dei sottogruppi 
tradizionali. L'obiettivo dello studio è anche quello di verificare se questi cambiamenti predicono 
esiti cardiovascolari. 
Materiali e metodi. 227 pazienti ad alto rischio cardiovascolare (pazienti con almeno due classici 
fattori di rischio cardiovascolare o con malattia cardiovascolare stabilita) sono stati reclutati per 
questo studio e seguiti per una mediana di 4 anni. Le sottopopolazioni monocitarie sono state 
quantificate e caratterizzate al basale utilizzando la citometria a flusso policromatica, in base 
all'espressione di CD14 e CD16; per ciascun sottogruppo sono stati determinati la frequenza e l’ 
intensità media di fluorescenza (MFI) di CD14 e CD16, valutando la loro distribuzione lungo il 
continuum monocitario. Queste caratteristiche dei monociti sono state studiate nei pazienti 
correlandole ai fattori di rischio cardiovascolare, alla prevalenza di malattia coronarica (CAD) e alla 
comparsa di eventi avversi cardiovascolari maggiori (MACE) durante il follow-up. 
Risultati. In relazione ai fattori di rischio cardiovascolare, nei pazienti con diabete di tipo 2 è stato 
osservato un aumento consistente dell’ intensità di fluorescenza del CD16 all'interno di ciascun 
gruppo di monociti, nonostante non si sia rilevato nessun cambiamento nelle loro frequenze. I 
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pazienti con malattia coronarica (CAD) al basale hanno mostrato un raddoppio nella frequenza dei 
monociti intermedi CD14++ CD16+ e uno spostamento di monociti classici e non classici verso 
quelli intermedi. Durante il follow-up, la morte cardiovascolare o eventi cardiovascolari si sono 
verificati in 26 pazienti, che hanno mostrato uno spostamento dei monociti simile a quelli dei 
pazienti con CAD al basale. Utilizzando il modello di Cox di regressione di rischio proporzionale, 
tra i parametri dei monociti, solo l'espressione del CD16, più elevata sui monociti classici, ma non il 
livello di monociti intermedi o di altri sottogruppi, predice indipendentemente gli eventi 
cardiovascolari avversi. 
Discussione e conclusione. I cambiamenti nei sottogruppi monocitari in pazienti con CAD e in 
pazienti evoluti in MACE durante il follow-up hanno suggerito uno “shift” dei monociti classici e 
non classici verso gli intermedi, mostrando cambiamenti fenotipici all'interno del continuum 
monocitario. Il ruolo predittivo dell’MFI del CD16 sui monociti classici evidenzia come il concetto 
di continuum monocitario possa essere utilizzato per modellare il rischio cardiovascolare più della 
frequenza delle diverse sottopopolazioni monocitarie. 
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ABBREVIATIONS 
 
ADA  American Diabetes Association 
AGEs  Advanced Glycation Products  
ATH  Atherosclerosis 
BMI  Body Mass Index 
CAD  Coronary Artery Disease 
CCR2  CC-receptor-2 
CD  Cluster of Differentiation 
CerVD Cerebrovascular Disease 
CKD  Chronic Kidney Disease 
CVD  Cardiovascular Disease 
CX3CR1 fractalkine chemokine receptor 
EMPs  Erythro-Myeloid Progenitors  
FITC  Fluorescein Isothiocyanate 
FMO  Fluorescence Minus One 
FSC  Forward Scatter 
GM-CSF Granulocyte Macrophage Colony Stimulating Factor 
HDL  High Density Lipoprotein 
HSC  Hematopoietic Stem Cell 
ICAM-1 Intracellular Adhesion Molecule-1 
INF- γ  Interferon-γ 
LDL  Low Density Lipoproteins 
LPS  lipopolysaccharides 
mAb  monoclonal Antibody 
MACE Major Adverse Cardiovascular Events 
MCP-1 Monocyte Chemotactic Protein-1 
MCSF  Macrophage Stimulating Growth Factor 
MFI  Mean Fluorescence Intensity 
MHC  Major Hstocompatibility Complex 
MP  Myeloid Precursor 
NO  Nitric Oxide 
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NOS  Nitric Oxide Syntase 
PAD  Peripheral Artery Disease 
PE  Phycoerythrin  
ROS  Reactive Oxygen Species 
SD  Standard Deviation 
SMC  Smooth Muscle Cells 
SR  Scavenger Receptors 
TIA  Transient Ischemic Attack  
TNF-α  Tumor Necrosis Factor-α  
T1D  Type 1 Diabetes 
T2D  Type 2 Diabetes 
VCAM-1 Vascular Cell Adhesion Molecule-1 
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INTRODUCTION 
 
1. INFLAMMATION AND ATHEROSCLEROSIS 
Atherosclerosis (ATH) is an inflammatory disease of the large arteries; it is a chronic process that 
causes thickening of the large and medium calibre arteries and a loss of elasticity of the arterial 
walls, which appear with the progress of age and can reduce or prevent blood flow. Clinically, ATH 
may be asymptomatic or manifest, with ischemic events on cerebral arteries, myocardial infarction 
and other effects such as renal failure, hypertension and aneurysms.1 It tends to manifest where the 
blood flow is not laminar, at bifurcations or curvature of the vessels. The traditional risk factors for 
atherosclerosis that stimulate the initial lesion have been known for a long time such as 
hyperlipidemia, hypertension, smoking, diabetes mellitus, infections and genetic abnormalities.2 It 
is now clear that atherosclerosis pathogenesis and complications are caused by inflammatory, 
thrombotic, metabolic and other mechanisms.3 
The critical endpoints of atherosclerosis are cardiovascular diseases (CVD) which are the main 
cause of death in developed countries.4 CVD include a lot of adverse events and vascular diseases, 
including coronary artery disease (CAD), stroke, infarction, peripheral arterial disease (PAD), 
which account for most cardiovascular morbidity and mortality.5 
 
In 1970, the Ross’s theory "Response to injury" was the first to question the "lipid theory" 
according to which atherosclerotic plaque was caused by an accumulation of cholesterol inside the 
vessel.6 But already in 1958, Poole and Florey claimed that following the deposition of cholesterol, 
the monocytes adhered to the endothelium and migrated through the endothelium rabbit aorta.7 
Several years later, Gimbrone proposed for the first time the concept of endothelial dysfunction 
highlighting the main role of healthy endothelium safekeeping against atherosclerosis: alteration in 
its normal functionality was at the base of atherosclerotic disease.8 In 1986 Ross revised his 
"Response to injury" theory claiming that an endothelial damage is the first major event leading to 
ATH9 and in 1999 published an important review in which he supports the idea that ATH is a 
chronic inflammatory disease in which cells of the immune system play a role of significant 
importance.2 Afterwards, several works sustain this hypothesis, considering that the adhesion of 
monocytes and lymphocytes to the activated endothelium represents the first important phase of 
atherosclerotic pathology. 
10 
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1.1 The atherosclerotic process  
At the beginning of the atherosclerotic process, there are two prominent pathological mechanisms: 
lipid accumulation in arteries and inflammation. Through these processes arteries lose their normal 
function, the lumen is constricted and an inadequate blood flow may provoke CVD including 
coronary artery disease and stroke.10 The events of ATH have been greatly clarified by studies in 
animal models.1 
1.1.1 Fatty streak formation 
The wall of normal arteries consists of three layers where the inner layer, or intima, consists of the 
endothelium and the basal lamina that borders the media, the middle layer is build up by smooth 
muscle cells and connective tissue, collagen and elastin. The outer layer, the adventitia, is 
composed of elastin fibers; it contains small blood vessels, the vasa vasorum, lymph vessels and 
nerves.11 
The first visible manifestation of ATH involves the formation of a lesion at intima level, defined by 
the name of “fatty streak”, which begins with activation of the endothelium, oxidation of low-
density lipoproteins (LDL), recall of macrophages at the inflammation site that incorporate the 
oxidized low density lipoproteins (oxLDLs) and subsequently they turn into “foam cells”.12,13 
At this stage, fatty streaks are constituted only by foam cells and lipids while T-cells and 
extracellular lipids are still present in reduced number. A classification of the American Heart 
Association divides atherosclerotic lesions into six types starting by isolated foam cells (called 
“lipid point”), through the fatty streak stage, atheroma, fibroatheroma, up to the most complicated 
lesion [Fig. 1].10 
 
Fig. 1. American Heart Association classification of human atherosclerotic lesions from the fatty streak (type I) to the 
more complicated type VI lesion. The diagram also includes growth mechanisms and clinical correlations.14 
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Not all fatty streaks are clinically relevant but they are precursors of more advanced lesions 
characterized by a necrotic core rich in lipids, debris and smooth muscle cells (SMCs). 
Calcification, ulceration at the luminal surface, and small vessels bleeding can increase the 
complexity of the plaques.1 The continuous intima’s thickening leads to the formation of the mature 
lesion, defined atherosclerotic plaque or atheroma, that is characterized by a great inflammatory 
condition and is rich in lipids, dead cells, immune cells (especially macrophages and T 
lymphocytes), endothelial vascular cells, SMCs and extracellular matrix.15 
Atheroma have a more complex structure than the fatty streak, invading often the artery’s lumen, 
consists of a central part, called core, which contains foam cells, lipids, dead cells and cell debris, 
surrounded by a cap of smooth muscle cells and collagen.15 Other cell types present at plaque level 
and described in literature are dendritic cells,16 Mast cell,17 a small number of B lymphocytes, 
natural killer T lymphocytes. The interface between core and fibrous cap is instead rich in T 
lymphocytes and macrophages [Fig.2].15 
 
 
 
Fig. 2. Cell composition of the atherosclerotic plaque. The atherosclerotic plaque has a core containing lipids and debris 
originated from dead cells. It also contains smooth muscle cells and collagen fibers, which have the task of stabilizing 
the plaque itself, immune cells, macrophages, T cells and mast cell.15 
 
 
12 
12 
 
Most of the immune cells located at plaque level are activated and produce pro-inflammatory 
cytokines such as interferon-γ (INF- γ) or tumor necrosis factor-α (TNF-α).12 
Plaque can develop to a more complex form: extracellular matrix secretes proteases and cells 
infiltrated in the plaque secretes cytokines, aggregation of cholesterol and formation of crystals 
leads to the formation of a “fibrous cap” that defines the plaque and prevents contact between the 
blood circulation and the prothrombotic material. Finally, the fibrous cap can break, causing the 
release of prothrombotic material in the bloodstream; this represents the most severe and damaging 
clinical event that can cause occlusion of arteries at the rupture site. At heart level, atherosclerosis 
can lead to myocardial infarction and cardiac arrest, while at cerebral arteries level it can cause 
ischemia or stroke. If the ATH also affects other branches of arteries, it can lead to renal 
dysfunction, hypertension and aortic aneurism.18 
1.1.2 Low-density lipoproteins 
Oxidation of low density lipoproteins (oxLDLs) plays a fundamental role in the intima’s chronic 
inflammatory reaction; the increased vascular permeability trapped LDL in the subendothelial 
space’s extracellular matrix.19 Reactive oxygen species (ROS) induce changes that triggers the 
oxidation of lipids.20 These oxLDLs are no longer recognized by LDL-receptors (LDL-R), but they 
bind "scavenger receptors" (SR): SR-A, CD36 and CD68. They introduce active macromolecules in 
the cells that engulf them and cause intracellular accumulation of cholesterol esters, responsible for 
the transformation in foam cells. 
Interaction with the corresponding LDL-R and SR (and the consequent generation of intracellular 
messengers, in particular ROS) and the introduction into the cell of oxidized products are the 
biochemical basis of the pathogenic action of LDL. The OxLDL activate transcription factors (NFk-
B) in the cells (endothelial cells, macrophages, smooth muscle cells), which induce the expression 
of genes coding for cytokines, adhesion molecules, growth factors and rise the inflammatory 
response [Fig.3].21 
 
 
 
 
 
 
 
Fig. 3. Effects of activation and infiltration of LDL in 
inflamed arteries. An excess of LDL infiltrates arteries in 
hypercholesterolemic patients. Oxidative and enzymatic 
modifications lead to the release of inflammatory cytokines 
that induce endothelial cells to introduce active 
macromolecules in the cells that engulf them and cause 
intracellular accumulation of cholesterol esters, responsible 
for the transformation in foam cells. 
13 
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1.1.3 Endothelial disfunction 
Over the years, animal models have been widely used in order to better understand and clarify the 
mechanisms of initiation of ATH. Hansson and Libby in 200615 and later Weber22 allowed to clarify 
the different phases of the inflammatory process during the formation of the atherosclerotic plaque. 
In particular, it is possible to highlight several sequential phases in the formation of lesions [Fig. 4]: 
● activation of the endothelium and increased expression of adhesion molecules, as vascular 
cell adhesion molecules-1 (VCAM-1) and intracellular adhesion molecules-1 (ICAM-1); 
● adhesion of monocytes to the endothelium and infiltration of other immune system’s cells in 
the intima; 
● accumulation and recall of additional cells by chemokines, for example the monocyte 
chemotactic factor (MCP-1); 
● transformation of monocytes into foam cells in response to cytokine production, such as 
macrophage stimulating growth factor (MCSF); 
● alteration of the stability of the plaque caused by infiltrated cells’ production of cytokines 
and enzymes, modification of the fibrous cap, which, can lead to plaque rupture and 
thrombosis, resulting in stroke or myocardial infarction.15 
Over the last 15 years, it has been established that endothelium is not a simple coating of cells on 
the inner wall of the arteries. Endothelial cells secrete a large variety of active molecules3. Healthy 
endothelium represents an important selective barrier for free passage of molecules and cells 
through the gap junctions; it is an endocrine and dynamic organ, which not only mediates 
endothelium-dependent vasodilation, but also actively inhibits leukocytes adhesion and their 
migration to the intima, as well as adhesion and platelet aggregation, proliferation of vascular 
smooth muscle cells and their migration. Inhibits coagulation, fibrinolysis and actively promotes 
and participates in immune and inflammatory reactions.23 
A great variety of stimuli, such as oxLDL, presence of free radicals caused by smoking, 
hypertension, diabetes, genetic alterations, high concentration of plasma homocysteine and 
infections, can cause endothelial dysfunction or activation. All these conditions lead to alterations in 
endothelial homeostasis and influence endothelium permeability, vasoconstriction, coagulation and 
triggers inflammatory and immunological reactions. Endothelial dysfunction has been shown to be 
one of the first signs in ATH, even in absence of angiographic evidence of disease. In the past, the 
14 
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reduced nitric oxide (NO) activity was one of the most significant markers also in detecting 
endothelial dysfunction.24 
 
Fig. 4. Endothelial dysfunction: increased endothelial permeability provokes an upregulation of endothelial adhesion 
molecules: leukocytes adhere to the endothelial cells and migrate into the artery wall. 
 
 
1.2 Innate and adaptive immunity in ATH  
As previously described, inflammation and immune response are key components of the 
atherosclerosis pathophysiology. 
ATH is characterized by the accumulation and modification of lipids in the vascular wall followed 
by infiltration of inflammatory cells. The cells involved in the initial phases and in the progression 
of atherosclerotic plaque, are both from the innate and the acquired immunity.25 
Elements involved in the innate immunity are monocytes, dendritic cells, mast cells and platelets 
and they all have a role in the pathogenesis of atherosclerosis.26 
The first step of the inflammatory process in atherosclerosis is the activation of monocytes from the 
arterial lumen to intima. Monocytes adhere to activated endothelial cells by leukocyte adhesion 
molecules.27 There are a lot of subtypes of adhesion molecules, for example VCAM-1, ICAM-1 and 
selectines [Fig. 5].15 
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Fig. 5. Recruitment, activation, and development of monocyte and macrophages in response to modified LDL in 
atherosclerotic lesions.28 
 
It is partly unclear which mediators stimulate the expression of these adhesion molecules. 
Monocytes are also recruited to the intima by specialized cytokines and chemokines, which attract 
attached monocytes to migrate into the intima. The most studied is the monocyte chemoattractant 
protein 1 (MCP-1) and its receptor CC-receptor-2 (CCR2). In experimental animal models it is 
proven that deficiency of MCP-1 and CCR2 reduce atherosclerosis.29 
In the intima, monocytes are activated and become macrophages with an increase of scavenger 
receptors and toll-like receptors (TLR).30 These receptors recognize a large amount of molecules 
including particles of ox-LDL, bacterial endotoxins, and fragments of apoptotic cells. These 
fragments are recognized and then phagocyte, especially LDL particles. If macrophages internalize 
enough lipid they become lipid rich foam cells. 
All these cells through the production of cytokines, ROS, proteinases, lipid mediators, factors of 
growth, promote the proliferation of smooth muscle cells, the deposition of the matrix extracellular, 
vessel remodeling, angiogenesis and further inflammation.25 
Among the cells of the acquired immunity, we find the Th1 lymphocytes which, by the production 
of cytokines such as INF-γ and TNF-α, promote the plaque development, exacerbating endothelial 
activation; and Th2 lymphocytes that produce anti-inflammatory cytokines such as IL-4 and IL-10 
with an anti-inflammatory action and reduction of endothelial activation and foam cell 
formation.31,32 
Finally, there are Treg lymphocytes with positive action on the plaque stabilization by production of 
anti-inflammatory cytokines and B cells. 
16 
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However, endothelial activation and the continuous recall of immune cells, both from innate or 
acquired immunity, leads to the progression of the lesion, to the migration of smooth muscle cells 
from the vascular medial layer and circulating progenitor cells contribute to the formation of the 
fibrous cap and to the stabilization of the plaque.  
Over the last 10 years, the role of T and B lymphocytes has always been recognized even if they are 
not necessary for atherogenesis they are able to modulate the progression of this disease, despite 
their relatively low number in the plaque.32 
In recent years, attention has focused on a specific subpopulation of T lymphocytes CD4+ CD25+ 
defined Tregs which contribute to the suppression of the immune response addressed either against 
the self that against the non-self.33 A reduction in the number of Tregs was observed in various 
autoimmune diseases;34 a study conducted on patients with coronary artery disease, suggested how 
an alteration of their function could represent a symptom of plaque instability.  
While the role of monocytes, macrophages, T and B lymphocytes, and platelets is well recognized 
in the context of the ATH, only recently emergent studies have provided evidence that poly-
morphonuclear cells (PMNs) have been overlooked in the pathogenesis of cardiovascular diseases. 
Migration and adhesion of PMNs to endothelial cells are critical events during inflammation.35 
PMNs, platelets and monocytes adhere to the activated endothelial cells and interact each other 
through aggregates, resulting in a greater adhesion of leukocytes to the endothelium.26 PMN, 
monocytes and endothelial cells create ROS in response to activation.32 ROSs have been implicated 
in the promotion of inflammation and proliferation of smooth muscle cells leading to increased 
development of atherosclerotic lesions.36 ROSs are responsible for the oxidation of LDL, 
contributing to the development of atherosclerosis.37 
1.3 Conventional risk factors for atherosclerotic disease 
A risk factor is something increasing the chance of developing cardiovascular disease. There is a 
vast amount of evidence that links “conventional” risk factors to atherosclerotic vascular disease, 
but only half of the cases of clinical atherosclerotic disease can be explained by them.38 However, 
certain conditions, traits or habits increases the chance of atherosclerosis development. Most risk 
factors including high cholesterol and LDL, low level of high density lipoprotein (HDL) in the 
blood, hypertension, smoking, diabetes mellitus, obesity, inactive lifestyle, age can be controlled 
and atherosclerosis can be delayed or prevented. 
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1.3.1 Non modifiable risk factors 
In the pathogenesis of atherosclerotic disease, non-modifiable risk factors can be identified, such as 
genetic predisposition, age and gender. 
Even in the absence of atherosclerotic pathology, aging produce a thickening of the vessel wall 
affecting the intima and the medium tunic with consequent increase in the vessel stiffness.  With 
regard to the formation of atherosclerotic plaques, the phenomenon of cellular senescence in 
endothelial cells typical of advancing age leads to increase the expression of pro-inflammatory 
molecules and decrease eNOS, contributing to the endothelial dysfunction and the passage of 
monocytes into the vessel wall. In addition there is a greater production of chemokines by smooth 
muscle cells that promotes the migration of inflammatory cells.39 Regarding sex, estrogens have a 
protective role against inflammation and atherosclerosis at endothelial level and in post-menopausal 
women there is an increased cardiovascular risk.40 
1.3.2 Modifiable risk factors 
Smoking is with no doubt recognized as one of the most important life style risk factors correlated 
to atherosclerotic lesions. 
Smoking causes damage and endothelial activation by inactivating NO through increased ROS 
production; increases the oxidation of pro-atherogenic lipids and interferes with the lipid profile 
leading to a decrease in HDL lipoproteins. It also induces a shift towards greater coagulability at the 
endothelial level: due to the alteration of platelet function and leads to an imbalance between anti 
and pro-coagulant factors. Smoking also leads to a systemic inflammatory response with an increase 
in leukocyte counts and an increase in PCR.41 
 
In contrast to smoking, hypertension is a silent cardiovascular risk factor. 
Hypertension acts as a risk factor through increased hemodynamic stress. The mechanism which 
can accelerate atherosclerosis is still unknown but in animal models, with high fat diet, is proven 
that hypertension accumulate fatty substances in the arterial walls. Perturbations of blood flow and 
hemodynamic forces contribute to endothelial dysfunction, as evidenced by the fact that 
atherosclerotic plaques are preferentially located in the bifurcations of vessel where blood flow is 
more turbulent.42 Increased production of adhesion molecules, altered production of extracellular 
matrix, haemostatic dysregulation are the results of these stimuli on endothelial cells. Furthermore, 
to support the role of hypertension, it has been shown that angiotensin II (a vasoconstrictive 
hormone) can cause endothelial dysfunction stimulating the production of superoxide anion by 
18 
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endothelial cells and vascular smooth muscle cells, and the expression of adhesion molecules (such 
as VCAM-1) on endothelial cells.42 Hypertension is related to an increased risk of myocardial 
infarction. 
 
Plasma cholesterol levels and particularly the accumulation of LDL represent the key events of the 
initial phases of atherosclerotic plaque development. In conditions of dyslipidemia there’s an 
increase of the plasma LDL that leads to a greater passage through the endothelial cells and their 
localization and retention at intima’s level.13 
The reduction of plasma cholesterol levels has proven effective in reducing the incidence of 
cardiovascular events in diabetic patients.43 
 
The hyperglycemia associated with type 1 (T1D) and type 2 diabetes (T2D) is another factor 
contributing to endothelial dysfunction. In type 2 diabetes, insulin resistance and dyslipidemia also 
contribute to endothelial dysfunction: hyperglycemia leads to advanced glycation end-products 
(AGEs) formation by endothelial cells (both intra and extracellular); these products interact with 
their receptors present on endothelial cells (RAGE), triggering the production of adhesion 
molecules, pro-inflammatory cytokines and a haemostatic imbalance with greater production of pro-
coagulant factors and reduction of NO production.44 
Diabetes also induces an inflammatory state through nuclear activation and translocation of 
transcription factors such as NF-kB and "activator protein 1" (AP-1). These factors determine the 
expression of genes responsible for the production of chemokines, pro-inflammatory cytokines and 
leukocyte adhesion molecules proving that diabetic patients have, on average, more severe 
atherosclerosis than not diabetic.45 
 
Obesity predisposes to insulin resistance and diabetes and also causes a condition of dyslipidemia, 
all risk factors of atherosclerosis.27 
Metabolic syndrome, defined as the presence of at least three factors including obesity, insulin 
resistance, reduced glucose tolerance, triglyceride increase, reduction of HDL lipoproteins and 
hypertension, is a set of risk factors for the development of atherosclerotic plaques.46 
 
  
19 
19 
 
1.4 Clinical results of atherosclerosis 
The atherosclerotic plaque instability can cause chronic or acute complications in the vessel and 
lead to cardiovascular disease. 
Stable atherosclerotic plaques, characterized by a relevant fibrous component, increase during time 
and determine arterial stenosis with reduction of the blood flow. This should cause stable angina at 
coronary level or peripheral artery disease at lower limbs level, usually manifests with claudication. 
However, the plaques complicate frequently with their rupture and the formation of thrombi, 
leading to the vessel occlusion. This situation occurs when the plaque is unstable and the 
inflammation state in the microenvironment damage the fibrous cap leading to its break, in addition 
to the erosion of the endothelial layer. Unstable plaques contain generally a high concentration of 
cholesterol; the rupture is preceded by the thinning of the fibrous, also promoted by a condition of 
hemodynamic stress.47 This fracture exposes the blood in contact with the lipid core, tissue factor, 
collagen and other elements that induce the formation of a thrombus.48 This situation predisposes to 
acute myocardial infarction (AMI) and ischemic stroke. At coronary level the atherosclerotic 
disease, plaque rupture and subsequent thrombus formation is the basic event in most cases of acute 
coronary syndrome, unstable angina, myocardial infarction and sudden death.49 
The progression of stenosis caused by atherosclerotic plaque can cause unstable angina.50 Plaque 
rupture can result in a geometric alteration which increases the degree of stenosis, regardless of the 
possible formation of the thrombus. Unstable angina can also be caused by transient thrombosis due 
to more limited plaque ruptures. The formation of the thrombus can also involve vasoconstriction, 
which contributes to the symptomatology, following serotonin and prostanoids released from the 
platelets. 
In myocardial infarction, however, plaque rupture is more relevant and leads to the formation of a 
stable thrombus that prevents blood flow. Sudden death is characterized by a fatal electrical 
instability resulting from ischemia.50 
Atherosclerotic plaque can in general also be complicated by the formation of an aneurysm: this 
depends on the destruction of the extracellular matrix as a result of increased activity of enzymes 
such as collagenases and elastase, which make the wall less resistant. This is also associated with a 
genetic predisposition and a situation of increased hemodynamic stress such as hypertension.49 
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2. MONONUCLEAR PHAGOCITIC SYSTEM 
Monocytes and macrophages are essential components of innate immunity; they play a pivotal role 
at tissue level both in the maintenance of steady state homeostasis and during inflammation, 
providing the starting process and extinguishing the immune response.51 
The mononuclear phagocytic system has historically been categorized by Ellie Metchnikoff into 
monocytes, macrophages and dendritic cells that exhibit their phagocytic ability during immune 
responses.52 All these cells are characterized by high heterogeneity and originate from a unique 
hematopoietic stem cell (HSC) from which derives a progenitor for monocytes and macrophages 
and a progenitor for dendritic cells [Fig. 6].53,54 According to a more remote view of the dynamics 
of the monocyte-macrophage system, monocytes egress from the bone marrow, circulate in the 
blood for few days and then migrate into the tissues, where they turn into macrophages: this occurs 
in steady state conditions and especially during inflammation.55 
 
Fig. 6. The monocyte-macrophage lineage. The hematopoietic stem cell is a unique multipotent progenitor cell, located 
in the bone marrow, which may differentiate either into a myeloid or a lymphoid precursor. This can divide either into 
the myeloid (blue) or plasmocytoid (green) lineage. The myeloid precursor has the possibility to migrate into the 
bloodstream and to develop into a monocyte. Monocytes migration to specific tissues and their differentiation takes 
place upon a stimulation of different cytokines, interleukins and other factors. Based on the localisation, monocytes 
become either interstitial dendritic cells, macrophages or microglial cells. Lymphoid precursor runs parallel with the 
myeloid one, but can directly differentiate into another type of dendritic cell, the plasmocytoid dendritic cell.56 
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This vision of the monocyte-macrophage system has changed over the years; in steady state 
condition, a macrophage component exists in tissues resulting from local tissue proliferation, 
independently from circulating monocytes; this cellular component derives from macrophages 
localized in tissues during embryogenesis that are maintained by self-renewal.57–60 
The fact that macrophages can have different origins (blood versus tissue monocyte) and exhibit 
differing phenotypes in some settings provided evidence of heterogeneity among phagocytic cells, 
but there is no lineage divergence. Recent data utilizing specific fate mapping technologies has now 
provided evidence for an embryonic origin of some tissue macrophages.61 These macrophages 
derive from two cell precursors during embryonic development: the erythro-myeloid progenitors 
(EMPs) of the yolk sac, which give rise to microglial cells; the EMPs progenitors resident in the 
fetal liver, which give rise to the residual macrophages of many other tissues.62 The contribution of 
circulating monocytes in steady state is actually limited to few tissues, for example intestine and 
dermis, with a rapid cell turnover that require the continuous migration of circulating monocytes to 
constitute the tissue macrophage population.63 
Tissue monocytes can differentiate into macrophages or dendritic cells:64 it has been shown that 
monocytes recruited at site of inflammation can also differentiate into inflammatory dendritic 
cells;65 in particular conditions monocytes can also differentiate into splenic dendritic cells, 
Langherhans cells and cutaneous dendritic cells.66 Overall, cells of the phagocytic-mononuclear 
system are interrelated and all these cells also share various markers. In humans, monocytes were 
initially defined on the basis of morphology and cytochemistry and later by polychromatic flow 
cytometry, based on light scatter properties and on cell-surface markers.67 
2.1 Monocytes 
Human monocytes represent the 3% to 8% of peripheral blood leukocytes. They represent an 
important role in innate immunity, inflammation, and tissue remodeling. This system is not antigen-
specific but it depends on pattern recognition receptors for conserved components of various 
pathogens, including their membrane, for example, lipopolysaccharides (LPS).30 They are 
characterized by high heterogeneity and plasticity, differing by phenotype, function and 
transcriptional profile:68 they phagocyte pathogens but they also promote the process of pathogen 
neutralization and elimination, producing cytokines, antigen processing and presentation.69 
Monocytes have a remarkable developmental plasticity and following their migration to tissues they 
can lose their characteristics and differentiate into various types of macrophages, but also give rise 
to cells of other lineages at appropriate culture conditions. Monocytes isolated from different 
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anatomical sites show various phenotypes and functions in accordance with local tissues demand.70 
2.1.1 Monocytes subsets 
The various and distinct roles attributed to monocytes in homeostasis, inflammation and repair lead 
to the concept of monocyte heterogeneity and the hypothesis that monocytes may commit to 
specific functions in the bloodstream,71 proposing the identification of different phenotypic subsets 
in humans and mice.72,73 
In the past, blood monocytes were analyzed using microscopy of stained slides or their light scatter 
properties in haematology analysers,55 but to analyze different monocyte subsets these approaches 
are no longer suitable. Flow cytometry has become the standard method for the analysis of 
monocyte subsets because it provides the capacity of simultaneous analysis of several surface 
markers combined with rapidity and observer independent collection of data from a large number of 
cells. 
Following the discovery of several monocyte subsets the CD14, part of the LPS co-receptor and the 
CD16, the FcγIII receptor with low IgG affinity, have emerged as standard markers for definition of 
monocyte subpopulations.73 
The current nomenclature of monocytes, defined by Ziegler-Heitbrock and colleagues in 2010,74 
distinguish three different subpopulations identified on the basis of the cell surface expression 
levels of these two markers (CD14 and CD16), detected with the use of monoclonal antibodies 
conjugated with fluorochromes by polychromatic flow cytometry [Tab. I].  
 
 
Tab. I. Definition of monocytes subsets in humans.74 
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They are distinguished as follows: 
• Classical monocytes (CD14++ CD16-) (also called Mon1), representing up the 85% of 
circulating monocytes. 
• Intermediate monocytes (CD14++ CD16+) (also called Mon2), 0-5% of circulating monocytes. 
• Non-classical monocytes (CD14+ CD16++) (also called Mon3), 10% of circulating monocytes 
[Fig. 7].68,75,76 
 
Fig. 7. Plot CD16 versus CD14. Distinction of monocyte subsets (classical, intermediate and non-classical, based on the 
CD16 and CD14 intensity). 
 
The subdivision of monocytes based on the expression of CD14 and CD16 through the use of flow 
cytometry requires first of all a morphological distinction of monocytes from other white blood 
cells using their dimension, physical and morphological characteristics (FSC/SSC plot).77  
Immune cells are usually characterized by the presence of cell surface marker, but a more 
sophisticated classification approach relies on gene expression profiling. Using mass cytometry by 
time-of-flight, Thomas and colleagues identified CCR2 (the receptor for MCP-1), CD36, HLA-DR, 
CD11c or LRP-1 as additional cell surface markers that provide better resolution of intermediate 
and non-classical monocyte subsets and also classical monocytes are identified with higher 
precision than using only CD14 and CD16.76,78,79 The additional use of a pan-monocytic marker in 
the quantification of the subtypes of circulating monocytes was recognized in the most recent 
consensus statements and was not available at the date of the analysis performed in the present 
study [Fig. 8]. 
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Moreover, the use of CD45 allows the exclusion of potentially overlapping CD45neg platelets, dead 
cells and debris.80 
 
 
 
Fig. 8. Gating strategy for monocytes analysis using a pan-monocytic marker: A) Distinction of monocytes based on 
physical and morphological characteristics in the FSC-A versus SSC-A plot. B) Use of a pan-monocytic marker, 
distinction of monocytes HLA-DR+. C) Distinction of monocyte subsets based on the surface expression of CD14 and 
CD16. 
 
However, most studies about monocyte subsets in atherogenesis have been performed using mice, 
the monocyte surface markers can't be compared to humans and other species, so it is difficult to 
extrapolate comparable data. 
Parallel researches in mouse models have defined mouse subsets by the differential expression of 
CD62L (L-Selectin), CCR2 (CC-Receptor-2), fractalkine chemokine receptor (CX3CR1) and Ly6C 
(part of the epitope of the GR1) and distinguished two mouse monocyte subsets: CD62L+ CCR2high 
CX3CR1low Ly-6Chigh monocytes (called Ly-6Chigh monocytes) and CD62L-CCR2low CX3CR1high 
Ly-6Clow (called Ly-6Clow monocytes).81,82 
The same differentiation in classical, intermediate and non-classical monocytes can also be applied 
to mice using the CD43 as a further marker and the three subpopulations are then identified:  
• classical monocytes: Ly-C6high CD43+ CX3CR1neg; 
• intermediates: Ly-C6high CD43++ CX3CR1pos; 
• non-classicals: Ly-C6low CD43++ CX3CR1high.83 
Various studies have investigated the homology between human and mouse regarding the monocyte 
subpopulations: gene expression seems to reveal that the classical and intermediate human 
monocytes would look more similar to the Ly-6Chigh murine monocyte population, and there would 
be homology between the human non-classical population and the murine Ly-6Clow subtype.84 
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2.1.2 Functional characteristics of monocyte subpopulations 
Several studies have been performed at molecular level to better characterize the three 
subpopulations. The identification of a peculiar gene expression profile within the individual 
subpopulations highlights their different functional capacities and phenotypic characteristics.85 
Monocyte subsets function has been more extensively studied in mouse models than in humans. In 
mice Ly6Chigh, inflammatory monocytes, circulate in the blood and following infection migrate into 
tissues, where they differentiate into macrophages or DCs, producing inflammatory cytokines and 
ROS, stimulating effector T-cell proliferation and mediating tissue repair. These cells also 
contribute to a population of monocyte-derived suppressor cells that inhibit T-cell function in 
cancer and autoimmune models. Ly6Clow monocytes adopt a patrolling phenotype, that allows them 
to monitor tissue damage.86–88 
In humans classical monocytes normally release pro-inflammatory cytokines like IL-6, are 
phagocytic and mediate a wide range of responses to pathogens.77,89,90 In contrast, the intermediate 
monocytes seem to release anti-inflammatory cytokines such as IL-10 and pro-inflammatory 
cytokines such as TNF-α and IL-1β.68,77,91,92 Finally, the non-classical subset seems to be involved 
in tissue repair [Tab.II].93 
Classical monocytes 
Represent approximately the 85% of total monocytes in the circulation, typically defined as 
CD14pos, CD16neg, CCR2high, CX3CR1low, CD62Lhigh in human and Ly6Cpos, CCR2high, CX3CR1low, 
CD62Lhigh in mouse. Classical monocytes are commonly viewed as pro-inflammatory and highly 
phagocytic.92 They are characterized by a greater expression of genes involved in cell adhesion and 
migration, genes encoding pathogen recognition receptors and genes involved in phagocytosis.76 In 
steady state conditions they supply the organs resident macrophage population with a rapid cell 
turnover such as the intestine63 and the skin94 and during inflammation they are recalled in the place 
of damage and infection by bacterial products (LPS) and cytokines or chemokines produced by the 
damaged tissue.59 
Monocytes CD16neg express high level of CCR2 and are more sensitive to CCL2 (also called MCP-
1), chemokine that recalls monocytes in the sites of inflammation. Stimulating with LPS, classical 
monocytes express various chemokines and cytokines, such as IL-6, IL-8, CCL2, CCL3.77,95 
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Intermediate monocytes 
Intermediate monocytes are cells of more recent discovery. The term "intermediate" is due to the 
CD16 expression. It seems to be a developmental relationship between these cells (from classical 
through intermediate to non-classical) during an infection or with macrophage colony stimulating 
factor (M-CSF) treatment, there is an increasing in the intermediate cells followed by an increase of 
the non-classical monocytes. Accumulating evidence demonstrates differences between 
intermediate and non-classical population in term of phenotype, function, gene expression and 
responses to disease. Intermediates are bigger, more granular and have higher surface expression of 
receptors involved in inflammation and immunity than non-classical: CD14, Toll like receptor-4, 
CCR2, CCR5, HLA-DR, and they are defined as CD14pos, CD16pos, CCR2dim, CX3CR1dim, 
CD62Ldim. 
Functional studies demonstrated that intermediates have a higher antigen presenting capacity, a 
higher phagocytic activity, a higher production of TNF-α, IL-6 and IL-1β in response to LPS and a 
higher rate of aggregation with platelets.76,96 Zawada and colleagues identified 258 genes up-
regulated in intermediate monocytes and 301 genes in non-classical. Intermediate monocaytes have 
a significantly higher expression of genes involved in the defense against pathogens (CD14) and 
MHC II–restricted antigen processing and presentation (HLA-DRA, CD74). In contrast, the non-
classical subset express higher levels of genes connected to MHC I–restricted processes (HLA-B, 
B2M), trans-endothelial mobility (LSP1) and cell-cycle progression (CDKN1C, STK10).68,97 
A large number of studies have examined blood monocyte subset phenotype and proportions in 
inflammatory diseases such as Crohn’s disease,98 sepsis,99 chronic kidney disease,100 obesity101 and 
diabetes mellitus and have revealed an expansion of the intermediate monocyte subset. In other 
studies, in vitro stimulation of intermediate monocytes with LPS resulted in a strong pro-
inflammatory cytokine profile. In a study of Cros and colleagues, intermediate monocytes produced 
the highest amounts of TNF-α and IL-1β, while additionally producing IL-6 and CCL3 at high 
levels similar to classical monocytes.92 In another study in vitro, intermediates and classical produce 
similar high levels of TNF-α while classical monocytes produce highest levels of IL-1β, and non-
classical monocytes produced little of either cytokine.102 
However, the pro-inflammatory profile of intermediates has not been consistently observed. For 
example, a study of Wong reported that intermediate monocytes were the lowest producers of TNF-
α, and IL-1β (highest production by non-classical monocytes).68 
Cros discovered a hierarchical cluster of gene expression profiles of monocyte subsets and indicated 
that intermediates are more closely associated with classical rather than non-classical, suggesting 
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that they may derived directly from classical monocytes.92 However, other two studies which also 
use a gene profiling approach with hierarchical clustering reported the opposite, and interpreted 
their results as indicating that intermediate and non-classical subsets are more closely related.68,97 A 
great number of the studies quote that they represent a highly phagocytic cell type associated with 
pro-inflammatory cytokines production. 
Non-classical monocytes 
Defined as CD14dim, CD16high, CCR2low, CX3CR1high, CD62Llow are characterized by a "patrolling" 
endothelial function,98 both in homeostatic and inflammatory conditions, as demonstrated by the 
wide expression of genes involved in the cytoskeletal rearrangement necessary for cellular 
movement.68 This "patrolling" function, due to the expression of the chemokine receptor CX3CR1, 
determines the retention of monocytes at the endothelial surface level and allows them to quickly 
arrive to the inflammation site:86 non-classical monocytes express high level of CX3CR1 and are 
more sensitive to CX3CL1 (fractalkine, chemokine linked to the membrane of activated endothelial 
cells).96 They have poor expression of genes involved in phagocytosis,98 a poor response to the 
stimulation with LPS, but a high expression of pro-inflammatory cytokines such as TNF-α and IL-6 
after activation in response to viruses and immune complexes.92 
 
All these considerations may conclude that these last two subsets should not be analyzed as a single 
population of CD16pos monocytes, as was intended a few years ago. There is still not enough 
understanding about the primary biological roles of these last two minor subsets of monocytes in 
contrast to classical monocytes, but the differences in their dynamics and function have been well 
documented. These dynamic changes of their characteristics suggest that their categorisation into 
discrete subsets may be an oversimplification and we support the idea that the whole monocyte 
population should now be redefined as a continuum of subsets. 
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Monocyte subset 
Definition markers 
CLASSICAL 
CD14
++
CD16
-
 
INTERMEDIATE 
CD14
++
CD16
+
 
NON CLASSICAL 
CD14
+
 CD16
++
 
References 
Proportion of 
overall monocytes 
85% 5% 10% [72,96] 
Corresponding 
mouse subsets 
Ly-C6
high
 CD43
+
 
 
Ly-C6
high
 CD43
++
 
 
Ly-C6
low
 CD43
++
 
 
[83] 
Size and granularity ++ +++ + [96] 
Functions Rapid recruitment 
to sites of 
inflammation 
High phagocytosis 
and subsequent 
production of ROS 
Contribute to 
macrophage 
populations in the 
intestine and skin in 
steady state 
Tissue specific 
surveillance in 
steady state for 
antigen with 
subsequent draining 
to lymph nodes 
with minimal 
differentiation 
Highly phagocytic and 
associated production 
of inflammatory 
cytokines 
Lipid scavenging with 
decreased cholesterol 
efflux.  
High basal level of ROS 
Low phagocytic 
activity 
Anti-inflammatory 
activity 
Healing 
Patrol endothelium 
 
[48,86,92,96] 
Gene profiles Pro-inflammatory 
mediators 
Wound healing 
Plastic response to 
stimuli 
MHCII antigen 
processing and 
presentation 
Pro-angiogenic 
Cytoskeletal 
mobility 
Complement 
components 
Phagocytosis 
Oxidative pathway 
components 
[76] 
 
Tab. II. Monocyte subsets properties. 
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2.1.3 The monocyte population: discrete entities or a functional continuum? 
Studies performed in order to characterize every monocyte subpopulations have demonstrated 
diversity but also overlap in gene expression among subtypes (especially between intermediate and 
non-classical monocytes).97 The gene profile of the monocyte subpopulations seems to detect a 
progressive increased expression of genes associated with maturation from classical monocytes to 
intermediate and non-classical monocytes.68,97,103 
Further studies, trying to understand the kinetic and correlation between different monocyte 
subpopulations, have shown a developmental relationship between them both in steady state 
condition and during inflammation, delineating these subpopulations as a continuum of differential 
stages.  
Recently, by in vivo labelling of human monocytes with deuterium, Patel and colleagues showed 
that monocytogenesis proceeds through the subsequent evolution of classical monocytes into 
intermediate and non-classical ones. After being released into the blood flow, classical monocytes 
leave the circulation by death or migration, while a minority of them differentiate into intermediate 
monocytes within 3 days. Intermediate monocytes, instead, circulate for 3 more days before 
transiting to non-classical monocytes. Finally, non-classical monocytes have the longest lifespan (7 
days), and they ultimately leave the bloodstream.104 
The same kinetic was observed and demonstrated in mice.105 Spleen represents a reservoir of 
monocytes outside the bone marrow, which mirror the circulating monocytes that can be mobilized 
when is necessary.51,106 
Regarding the expression of CD14 and CD16, markers considered for the subdivision into 
monocyte subpopulations, there is a progressive decrease of the CD14 expression and an increase in 
the expression of the CD16, starting from the classical monocytes and passing through the 
intermediate and non-classical state.68 
Many other markers characterize the monocyte surface. Some markers have shown their gradual 
increase/decrease depending on the developmental relationship between the subpopulations,68 for 
example it was observed that the intermediate monocytes express some surface markers at an 
intermediate level and intensity between classical and non-classical.85 Other markers have instead 
shown a greater expression in the intermediate monocytes than the other subpopulations conferring 
to these cells certain phenotypic and functional characteristics.103,107 
In line with this consideration, Hijdra suggested that the monocyte population can be hypothetically 
divided into a greater number of sub-populations than the traditional division, representing the 
monocyte subpopulations as a continuum [Fig. 9]. 
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Fig. 9. Example of the subdivision of the monocyte population into a larger number of subpopulations suggested by 
Hijdra and colleagues, based on the expression of CD14 and CD16 (the subpopulations are indicated with G1-G10) , 
and respective changes in the different surface markers expression.103 
 
Dynamic changes of monocytes subsets may occur during the course of disease, such as systemic 
inflammation104, and following pharmacologic treatment. 
Monocytes have been variously investigated in the cardiovascular pathology and frequency and 
phenotype alterations have been identified and suggest the ability of such cells to change along their 
continuum in relation to the circumstances.108 On the contrary, some studies have highlighted the 
distinctive features of the individual sub-populations, representing them as discrete entities with 
their own functional and phenotypic characteristics.76,109 
For this reason, the quantification of different subsets in peripheral blood may become useful for 
diagnosis and follow-up in human diseases, and in particular a baseline assessment might be used as 
a predictive parameter or as a biomarker for future cardiovascular events.110 
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2.2 Macrophages 
Macrophages are cells with great variability and plasticity, which can respond to environmental 
signals by changing their phenotype and functional properties. They are in fact a heterogeneous 
cellular population, consisting of specialized macrophages depending on the environment where 
they are found.82 
They have a central role in the maintenance of tissue homeostasis, removal of cellular debris, 
apoptotic cells and tissue remodeling products; this process does not provide for an immune 
response and does not involve, if not in a small amount, the production of immune mediators by 
macrophages. They act in case of necrosis, stress, trauma, tissue inflammation: phagocytosis of 
necrotic debris leads the activation of signal pathways, which cause alterations in the expression of 
surface proteins and production of cytokines and pro-inflammatory mediators, defining them 
activated macrophages.111 
Activated macrophages are “paradigmatically” divided into two groups:  
• M1 macrophages, with a pro-inflammatory phenotype; 
• M2 macrophages, correlated with an anti-inflammatory function and tissue repair.112,113 
 
This subdivision represents the two extremes of a continuous distribution of the same population 
environment and cytokine equilibrium dependent.114 
M1 macrophages, characterized by high activity against bacterial and tumor cells, are also called 
classically activated macrophages, and are the result of a macrophage differentiation that occurs in 
the immune response cell-induced.  
For the M1 differentiation is necessary a stimulation with INF-γ and TNF-α. In particular, a 
constant stimulation with INF-γ, produced by NK cells in a transient manner and by Th1 in a stable 
manner, is necessary; TNF-α, on the other hand, is produced by macrophages themselves following 
the stimulation of the TLR and acts in an autocrine way, produce INF-β, which acts similarly to 
INF-γ.115 
Also the macrophage colony stimulating factor (GM-CSF) produced by a lot of cells, including 
macrophages and parenchymal cells, can lead to a differentiation versus M1 direction, through a 
signal pathways stimulated by INF-γ and TNFα.113 M1 macrophages produce pro-inflammatory 
cytokines such as IL-1, IL-6, IL-12, IL-18, IL-23, IL-26 and promote Th1 and Th17 responses.111 
More precisely, INF-γ leads to the transcription of genes for cytokine receptors, markers of cell 
activation, cell adhesion molecules, pro-inflammatory cytokines, chemokines (e.g. CCL2), antigen 
presentation molecules (for example Major Histocompatibility Complex, MHC).113 
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M1 macrophages are characterized by the expression of CD68 and CCR2.116 
Signals from cells of innate and acquired immunity can also lead the differentiation in M2. 
Tissue damage produce anti-inflammatory cytokines, such as IL-4, which directs a macrophage 
differentiation in the M2 direction; IL-13 also directs differentiation in the M2 direction. These 
macrophages produce extracellular matrix components, very few pro-inflammatory cytokines and 
have a poor ability to present the antigen to T cells.115 They are characterized by the expression of 
CX3CR1, CD163, CD206.117 Within M2 macrophages we can distinguish an M2-like category, 
which is activated by IL-10, glucocorticoids (released in stress situations), or molecules released by 
apoptotic cells. This kind of macrophages shares part of the characteristics of M2 but differs from 
these, especially as regards the cytokines production and phagocytic capacity.114 
Similarly to the concept of monocyte continuum the traditionally M1/M2 macrophage polarization 
paradigm assume incremental differences in the expression of cell surface markers and cytokines 
confirming that they must be considered as a continuum rather than as distinct phenotypes and this 
is confirmed by gene expression studies.115,118–120 
 
  
Fig. 10. A summary of the monocyte macrophage system in ATH and CVD.115 
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3. ROLE OF MONOCYTES AND MACROPHAGES IN 
ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES  
Monocytes, macrophages and dendritic cells are essential to the development of atherosclerosis.15 
They play a fundamental role in atherogenesis both in the early stages of lesion formation and in the 
subsequent phases when atherosclerotic plaque is already formed. In the early stages circulating 
monocytes, recalled by chemokines, adhere to activated endothelial cells expressing adhesion 
molecules; then, following the chemokine gradient, monocytes migrate into the intima layer of the 
vessel.26 
A great amount of works underlines the monocyte heterogeneity at the atherosclerotic plaque level. 
Studies on mice show how the chemokine receptors expressed by monocytes are involved in their 
migration to the plaque: monocytes Ly-6chigh use both CCR2 (chemokine receptor of CCL2) and 
CX3CR1 (receptor of CX3CL1, expressed at low level by monocytes Ly-6chigh), while the Ly-6clow 
monocytes seem to use more CCR5 (which binds chemokine CCL5); anyway, CCR2, CCR5 and 
CX3CR1 are essential for the extravasation of monocytes at plaque level.105 
In humans, while classical monocytes express previously CCR2 and non-classical monocytes 
CX3CR1, intermediate monocytes are characterized by the higher expression of CCR5 and co-
expression of the other two receptors.100 Intermediate monocytes are the most involved in the 
development of atherosclerosis:121 once migrated to the vessel wall, monocytes become 
proliferating macrophages, macrophages interact with the oxLDL and then trigger the macrophages 
signaling pathways which evolve towards the inflammatory type, M1.122 
Macrophages contribute to the formation of the necrotic core of plaque and to the production of 
inflammatory signals; they are also involved in the neo-angiogenesis of atherosclerotic plaque, 
which is stimulated by inflammation and hypoxia and contributed to the plaque growth; they are 
also related to the instability of the plaque itself.123 
In conditions of cardiac damage (for example AMI) or haemodynamic stress, there’s a great 
recruitment of circulating monocytes to restore the lower level of resident tissue macrophages 
caused by ischemia;124 in these conditions a large amount of macrophages, at cardiac tissue level, 
originate from circulating monocytes, and not from proliferating resident macrophages, which then 
differ in pro-inflammatory macrophages.60 
After cardiac cells death, granulocytes, especially neuthrophils, and then monocytes are recalled by 
inflammatory signals from the damaged area. Studies on mice demonstrated that the damaged heart 
cells modify their chemokine expression over time: CCR2 shows a spike during the first phase; 
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CX3CR1 is most expressed in the second phase. So at first time (1-4 days after AMI) Ly-6chigh 
monocytes are recruited, with their pro-inflammatory and phagocytic function and later (after 5 
days), Ly-6clow monocytes migrate with a reparative function. Subsequently, monocytes can 
differentiate into macrophages, depending on the cytokine tissue environment.125  
3.1 Monocyte subsets, risk factors and cardiovascular diseases 
Monocytosis was found to predict cardiovascular events in some studies126 but not in others,127 and 
lymphocyte counts seem to be inversely correlated with coronary disease and its complications.128 
While differences in study design may account for some discrepancies regarding the correlation of 
monocyte counts and adverse cardiac events in epidemiological studies, flow cytometry has allowed 
for more sophisticated risk stratification. 
Alterations in frequency or in surface markers expression of the various monocyte subpopulations 
are related to inflammatory and pathological conditions, typical of cardiovascular diseases. Patients 
with one or more traditional cardiovascular risk factors or patients with cardiovascular disease were 
recruited in a large amount of study in order to evaluate the correlation with alterations in the 
frequency of traditional monocyte subsets (classical, intermediate, and non-classical). 
The identification of changes in the frequency or phenotype of mononuclear cells in inflammatory 
conditions could be a valid prognostic marker in the field of risk factors and cardiovascular 
diseases108 and support the idea of a continuum of the monocyte population with changes related to 
different conditions. 
A weak but positive correlation of CD14+ CD16+ monocytes with total plasma cholesterol and 
triglyceride levels was first described in 1999 in hypercholesterolemic patients with a positive stress 
ECG indicative of coronary heart disease.129 
The number of CD16+ monocytes but not overall monocyte counts positively correlate with Body 
Mass Index (BMI), insulin resistance/diabetes and intima-media-thickness. Weight loss after gastric 
bypass surgery in severely obese patients is associated with a significant reduction of 
CD16+monocytes.100,130 Likewise, exercise training reduced the number of CD16+ monocytes in a 
physically inactive study population.131 
Regarding obesity, an increased percentage of intermediate monocytes was found in obese patients 
with insulin resistance, but not in obese without insulin resistance, and in both the categories a 
reduction in the proportion of intermediate monocytes was shown after one hour of aerobic 
exercise, demonstrating that changes within the monocyte continuum can take place even in the 
short term.132 
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In addition, a study of 569 patients shows that CD16+ monocytes are increased in patients with high 
BMI, and the increase in frequency of CD16+ monocytes is also correlated with subclinical 
atherosclerosis.80 
An alteration in all monocyte subpopulations can be observed in a non-optimal lipid profile context, 
traditional risk factor for atherosclerotic disease; although intermediate monocytes are by definition 
more inflammatory (they have a higher capacity to produce inflammatory cytokines), a transition to 
an inflammatory state (with increased cytokine production) of all monocyte subpopulations has 
been observed.133 
Intermediate monocytes are generally implicated in cardiovascular disease,134 and their participation 
in the atherosclerotic plaque formation process is well known.100,135 In this context, a study shows 
that patients with CAD have higher percentages of CD16+ monocytes than controls.136 
In addition, an increase in the frequency of intermediates and a decrease in non-classical, the day 
after the event, was observed in most patients hospitalized for AMI compared to controls, with a 
return to pre-event values after about 30 days.137 Similar alterations were observed in stroke 
patients: an increase in intermediate monocytes and a simultaneous reduction of non-classical the 
days following the event was demonstrated.138,139 On the other hand, considering other surface 
markers, phenotypic alterations in all monocytes have been observed in patients with coronary 
disease: an increase in IL-6R expression on classical and intermediate (highlighting the role of 
inflammatory cytokines in atherosclerosis); an increase of CXCR4 chemokine receptor on non-
classical and intermediate (favoring their recruitment at vascular level); and an increase in the CD34 
expression in all monocytes.140 
However, in studies conducted by our research group was detected no significant effect of 
traditional risk factors on the levels of traditional classical (CD14++CD16−), intermediate 
(CD14++CD16+), and non-classical (CD14+CD16+) monocyte subsets.116,117,141 
In a study carried out measuring the frequency of monocyte subpopulations in pre-diabetic subjects 
there wasn’t significant change in their frequency compared to controls117. Even in subjects with 
type 2 diabetes, no significant difference in the frequency of monocyte subpopulations has been 
demonstrated.116 However, in patients with type 2 diabetes, a state of increased activation of innate 
immunity was observed, with a greater expression of inflammatory cytokines by neutrophils and 
monocytes;142 another study demonstrates an increase in CD11b and CD66b (integrins involved in 
cell adhesion and migration) on both granulocytes and monocytes, and also in the CD16 expression 
on monocytes.143 It has been shown that even in patients with hypercholesterolemia there are no 
changes in the frequency of monocyte subpopulations compared to controls.141  
36 
36 
 
Similarly, another small study in 26 patients referred for elective coronary angiography doesn't 
point out considerable differences in the percentages of classical, intermediate, non-classical and the 
whole monocyte population between patients with and without hypercholesterolemia.144 
3.2 Prognostic value of alterations in monocyte subsets in cardiovascular disease 
Some studies have also focused on the predictive role of the alterations of the monocyte 
subpopulations found in the patients being studied. 
In this regard, intermediate monocytes appear to have a prognostic relevance.134 This is 
demonstrated, in a large prospective cohort of 951 patients undergoing elective coronary 
angiography, increased numbers of intermediate CD14++ CD16+ monocytes independently predicted 
cardiovascular death, myocardial infarction and stroke over a period of 2 and a half years.145 
This association can also be applied in patients on dialysis with chronic kidney failure in patients, in 
addition to the detection of an increase in CD16+ monocytes, the association between the increase in 
intermediate monocytes and the incidence of cardiovascular events has been demonstrated.100,146 
CD14+ CD16+ monocytes but not total monocyte counts predict cardiovascular events in patients 
with chronic kidney disease and end stage of renal disease on dialysis, a patient population at 
increased risk for atherosclerotic complications.147 
Interestingly however, among a study population with stable coronary artery disease, those patients 
with more than 5 cardiovascular risk factors and especially with a positive family history for 
coronary artery disease presented relatively higher percentages of CD14high CD16− 
monocytes.100,148.  
In a general population (n=659) with no known cardiovascular disease, increased numbers of 
circulating classical CD14++ CD16– monocytes predicted cardiovascular events within a mean of 
15-year follow-up independently of sex, age, and classical cardiovascular risk factors.149 This is the 
first large cohort study identifying increased numbers of classical CD14high CD16− monocytes as an 
independent risk factor for ischemic cardiovascular events in a general population. 
An increase in intermediates, 2 days after the initial event, was found in stroke patients and this 
correlated with mortality inversely.139 
A cross-sectional study in 53 patients with stable CAD and 50 age- and sex-matched healthy 
controls highlights significant differences in monocyte phenotype in cardiovascular disease, which 
were differentially attributable to the 3 monocyte subsets defined according to contemporary 
nomenclature, but not in monocyte subsets proper.96 
During AMI, the number of circulating classical and intermediate monocytes increased acutely over 
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3 days and were associated with impaired left ventricular function and larger infarct size.150 
By contrast, it has been observed in patients with more advanced stages of peripheral artery 
occlusive disease, an increase in CD14++ CD16+ intermediate monocytes, suggesting that they have 
a pro-inflammatory function and can represent a promising biomarker for disease progression.151 
However, it has been acknowledged that other conditions, a hypertension and coronary artery 
disease, may be related to significant changes.152 
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AIM OF THE STUDY 
 
The identification of new prognostic markers able to predict the incidence of cardiovascular events 
is an important topic of the last years. Many studies have been performed on the monocyte 
population involved in pathological conditions related to cardiovascular disease. 
It is well established that alteration in the frequency of monocyte subpopulations is associated with 
cardiovascular disease and can provide information about the incidence of cardiovascular events. 
Considering the monocyte population as a continuum of different subpopulations capable of 
continuous phenotypic adaptations, we tried to investigate the possible variations in the frequency 
and their phenotypic and functional alterations within this continuum, and we tried to determine the 
correlations between these alterations, traditional risk factors and cardiovascular diseases. 
The aim of this study was  to investigate whether any cellular changes within the monocyte 
continuum, in the context of risk factors and cardiovascular diseases, can be better appreciated by 
analyzing the mean fluorescence intensity of CD14 and CD16, monocyte cell surface markers, 
rather than the frequency of the three traditional subpopulations, and whether these changes may aid 
additional information and should be a more useful predictive value for the incidence of 
cardiovascular events. 
Finally, their distribution along the CD14/CD16 continuum could be represented by a 90° curve. 
The position of each cell on the curve could be analyzed using a “clock rule” and described by an 
angle that could capture CD16 and CD14 expression as a single number, the angular coefficient. 
We applied this concept to evaluate whether this more objective approach should give better 
information associated to cardiovascular risk or best predictive of incident MACE. 
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MATERIALS AND METHODS 
 
1. Patients’ characteristics  
The study was approved by the Ethical Committee of the Province of Padua, was conducted in 
accordance with the Declaration of Helsinki and all patients provide a written informed consent. 
Patients were recruited from the Outpatient clinic of the Division of Metabolic Disease of the 
University Hospital of Padua from March 2011 to June 2015. 
The inclusion criteria in this study were: 
● age 18-80 years; 
● presence of at least 2 classical cardiovascular risk factors (diabetes, obesity, hypertension, 
smoking) or established cardiovascular disease. 
The exclusion criteria in this study were: 
● acute infections or inflammatory conditions; 
● recent trauma or surgery; 
● autoimmunity; 
● organ transplantation; 
● pregnancy; 
● lactation; 
● inability to provide informed consent. 
For all patients we collected the following data: 
● Anthropometric data: age, sex and Body Mass Index (BMI). 
● Presence of traditional cardiovascular risk factors: pre-diabetes and type 2 diabetes, 
hypertension, obesity, dyslipidemia, active smoking, chronic kidney disease (CKD). 
● Presence of atherosclerotic CVD: CAD (coronary stenosis at coronary angiography, 
symptomatic or asymptomatic); PAD (claudication, rest pain, ischemic wound ulcers with 
evidence of leg ischemia at ultrasound examination or angiography); CerVD, a past history 
of stroke or transient ischemic attack, or the presence of ≥30% stenosis of extracranial 
carotid arteries).  
● Data collected on medication. 
For each patient, starting from weight and height, was calculated the BMI (Kg/m²). 
Active smoking was considered as one or more cigarettes for a day.  
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Pre-diabetic patients and patients with T2D were defined according to the ADA (American 
Diabetes Association) guidelines.153 According to these guidelines for the diagnosis of diabetes, one 
of the following conditions is required: HbA1c ≥ 6.5%; fasting plasma glucose ≥126 mg/dl (7 
mmol/L); blood glucose ≥200 mg/dl 2 hours after OGTT; plasma glucose random ≥200 mg/dl (11.1 
mmol/L) in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis. For the 
diagnosis of pre-diabetes, one of the following conditions must be present: fasting plasma glucose 
between 100 mg/dl (5.6 mmol/L) and 125 mg/dl (6.9 mmol/L) (IFG); glycemia between 140 mg/dl 
(7.8 mmol/L) and 199 mg/dl (11.0 mmol/L) after 2 hours from OGTT (IGT); Hb1Ac 5.7-6.4%.153 
The presence of hypertension has been defined as PA ≥140/90 mmHg, or as an antihypertensive 
therapy.  
Obesity has been defined as BMI ≥30 kg/m².  
The condition of dyslipidemia was considered as a non-optimal lipid profile: total cholesterol >200 
mg/dl, LDL cholesterol >100 mg/dl, HDL cholesterol <40 mg/dl or triglycerides >150 mg/dl. 
The glomerular filtration rate was defined according to the CDK-EPI formula154 and the condition 
of chronic renal failure was identified as a glomerular filtration rate estimated with this formula 
infer to 60 ml/min/1.73 m² of body surface area. 
The presence of CAD was defined by the presence of significant coronary stenosis (symptomatic or 
asymptomatic) on coronary angiography confirmation, or as a history of a previous acute coronary 
syndrome.  
PAD was defined as the presence of symptoms/signs related to reduced blood flow, such as 
claudication, pain at rest, ischemic ulcers, together with demonstration by ultrasound or 
angiography of effective ischemia in the lower limbs.  
CerVD has been described as a history of stroke or transient ischemic attack (TIA), or as a presence 
of a ≥30% stenosis of the extracranial carotid arteries. Finally, atherosclerotic cardiovascular 
disease was defined by the presence of one of the three previous arterial pathologies, or a 
combination of the three.  
On the other hand, have been considered the therapy in progress: ACE inhibitors and aldosterone 
receptor antagonists, antihypertensive drugs, antiplatelet agents, statins, hypoglycemic agents and 
insulin. 
2. Follow up and definition of MACE 
Patients were followed with a 4.2 years median follow-up (IQR 3.1-4.8), by routine visits, 
telephone contacts and access to health electronic chart records and death registry.  
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During follow-up, in these high-risk patients was considered the incidence of major adverse 
cardiovascular events (MACE). 
The cause of death was considered to be cardiovascular in case of: 
- sudden death; 
- death occurred within 14 days after an AMI; 
- death occurred after worsening symptoms and/or signs of heart failure; 
- death occurred within 30 days after a stroke; 
- death due to another documented cardiovascular cause (e.g. dysrythmia, pulmonary 
embolism or intervention, non-fatal myocardial infarction, non-fatal stroke, unstable angina, 
heart failure and death for cardiovascular reasons); 
- death not attributed to a not-cardiovascular cause were presumed to be cardiovascular. 
Non-fatal myocardial infarction was defined by the presence of at least 2 of the following 3 criteria: 
1. increasing of cardiac biomarkers; 
2. ECG changes consistent with new ischemia; 
3. imaging evidence of new non-viable myocardial  or new wall motion abnormalities.  
Non-fatal stroke was defined as the sudden appearance of signs/symptoms referred to a neurological 
deficit (for example emergence of hemiplegia, hemiparesis, loss of sensibility of one side of the 
body, alterations of the state of consciousness, dysphasia/aphasia) with a duration ≥24 hours (or 
with a duration <24 hours if the event has been associated with pharmacological treatment, or in the 
presence of available brain imaging showing a new hemorrhage or ischemia, or resulting in death), 
later confirmed by a neurology specialist or by brain imaging. 
Unstable angina has been defined as resting, new onset or as an aggravation of a pre-existing angina 
in absence of cardiac biomarkers elevation, but in the presence of a new or a worsening ST-T on 
ECG, or evidence of ischemia by cardiac imaging, or evidence of ≥70% stenosis in an epicardial 
coronary artery.  
Heart failure was defined by the presence of typical symptoms/signs or their worsening (dyspnoea, 
orthopnea, paroxysmal nocturnal dyspnea, pulmonary edema, pulmonary basilar crackles, jugular 
venous distension, third heart sound or gallop rhythm, radiologic evidence of worsening heart 
failure), requiring the initiation of new therapy or an increase in doses in case of therapy already in 
place (diuretics, ionotropes, vasodilators), supported by an increase in biomarkers such as brain 
natriuretic peptide (BNP).  
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3. Flow cytometry 
Flow cytometry is a powerful tool to evaluate the characteristic of cells including particle’s relative 
size, relative granularity or internal complexity, and relative fluorescence intensity. These 
characteristics are determined using an optical-to-electronic coupling system that records how the 
cell scatters incident laser light and emits fluorescence. Fluorescence emission might be associated 
to dyes or conjugated monoclonal antibodies (mAb), which specifically bind molecules on the cell 
surface or intracellular components of the cell, allowing the identification of different cell types 
within a heterogeneous population. 
A flow cytometer consists of three main systems: 
• a fluidic system, which transports particles in a suspension to the laser beam for interrogation; 
• an optic system, which consists of lasers to illuminate the particles in the sample stream and 
optical filters to direct the resulting light signals to the appropriate detectors; 
• an electronic system, which converts the detected light signals into electronic signals that can be 
processed by the computer [Fig.11]. 
 
Fig. 11. Schematic organization of a flow cytometer: fluidic, optic and electronic systems. 
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For optimal illumination, when a cell suspension is run through the cytometer, sheath fluid is used 
to hidrodynamically focus the cell suspension through a small nozzle, causing cells to pass through 
a laser beam one cell at a time. 
When particles pass through the laser intercept, they scatter laser light. Moreover, any fluorescent 
molecules present on the particle fluoresce. The scattered and fluorescent light is collected by 
appropriately positioned lenses. Light scattering properties of each cell are analyzed by different 
detectors. Detectors aimed directly in line with the laser beam (forward scatter, FSC) determine the 
cells size; while detectors that are addressed perpendicular to the laser beam (side scatter, SSC) 
assess the granularity within the cytoplasm and the complexity of cells. Additional detectors are 
used to determine the amount of fluorescent intensity emitted by individual cells, which 
corresponds to the number of receptors expressed by the cells. The fluorescent data is translated into 
information and plotted into a single-dimension histogram that demonstrates size, granularity or 
expression intensity of an antibody. Multiple parameters can also be displayed using a dot plot, 
which shows expression of up to two fluorochrome-labeled receptors, size versus granularity, or a 
combination of these factors. 
 
Fluorochrome λ excitation λ emission 
Fluorescein Isothiocyanate (FITC)   488 nm 530 nm 
Phycoerythrin (PE)   488 nm 585 nm 
Peridinin-Chlorophyll Protein/Cyianine (PE-Cy5.5) 488 nm 690 nm 
Alexa Fluor 647 633 nm 668 nm 
 
Tab. III. Examples of fluorochromes specification used for a polychromatic flow cytometric analysis. 
 
The emission spectra of different fluorochromes [Tab. III] might overlap with the emission spectra 
each other. Whenever the fluorescence emission of one fluorochrome is detected in a detector 
designed to measure signal from another fluorochrome, spillover occurs. To correct the spectral 
overlap, a process of fluorescence compensation is used. Compensation aims to remove the signal 
from a given fluorochrome from all neighboring channels where it is also detected, in order to 
ensure that the fluorescence detected by a particular detector derives exclusively from the 
fluorochrome that is being measured. For this reason, fluorescence minus one (FMO) controls, 
containing all the antibodies to be tested in the experiment except for one, were considered as 
negative control: FMO controls are required to understand how other fluorochromes of the panel 
affect the left out parameter. 
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3.1 Flow cytometry protocol 
Identification and quantification of monocytes subtypes was performed at baseline on fresh blood 
samples, within three hours after collection, using polychromatic flow cytometry. 
For analysis of the cell surface expression patterns, peripheral blood of every patients was stained 
with a cocktail of monoclonal antibody (mAb) specific for surface antigens: 
• 10µL of mAb anti-CD16, FITC conjugated (Beckman-Coulter, clone 3G8); 
• 10µL of mAb anti-CD14, PE conjugated (Beckman-Coulter, clone RM052). 
100µL of whole blood was added to each tube, vortexed gently and incubated for 15 minutes in the 
dark at room temperature. Then 4 ml of 1X lysing solution of ammonium chloride (NH4Cl) were 
added, inverted to mix and incubated for 10 minutes at room temperature. After lysis was 
completed, indicated by the clearness of the sample, each sample was centrifuged at 1600 rpm at 
room temperature for 5 minutes and supernatants were decanted. Pellets were then resuspended in 
200µL of PBS and analyzed by flow cytometry. A total amount of 100.000 cells was recorded for 
each tube. 
All measurements were performed on a BD FACS CantoII flow cytometer (BD Biosciences; San 
Jose, CA) equipped with a blue laser (488 nm), a red laser (633 nm) and a violet laser (405 nm) and 
analyzed by BD FACSDiva® software (Becton Dickinson, San Jose, CA). 
The analysis was essentially conducted according to the minimal requirement suggested by the joint 
consensus document of the European Society of Cardiology (ESC) Working Groups 
“Atherosclerosis & Vascular Biology and Thrombosis”.76 
We first performed a stringent monocytic “morphological gate” in the SSC-A versus FSC-A plot, 
then based on the combination of the CD14 and CD16 expression intensity have been described and 
characterized three discrete subpopulations of monocytes in the plot CD14 versus CD16: 
● classical monocytes CD14++CD16- cells: defined as CD14high (about 104) CD16 low/neg; 
● intermediate monocytes CD14++ CD16+ cells: CD14high CD16pos (about 104); 
● non-classical monocytes CD14+CD16+ cells: CD14low (about 102-103) CD16pos.74 
However, definition of CD16neg, CD16dim and CD16high cells should be subjective and show inter-
individual variability. 
In addition, within each of these gates and for the total monocyte population we recorded the mean 
fluorescence intensity (MFI) of the CD14 and the CD16 expression and the respective standard 
deviations (SD) to precisely position monocytes and the different subsets along the continuum of 
the CD14/CD16 plot. 
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4. Statistical analysis 
Continuous variables are expressed as mean ± standard error, whereas categorical data are 
expressed as percentage.  
Non-normal variables were log transformed before statistical analysis. 
Comparison between two or more groups were performed with unpaired Student’s t-test. 
Owing (caused by) the very large number of comparisons, the Bonferroni correction was used to 
adjust for multiple testing. 
Event-free survival was analyzed by Cox proportional hazard regression models. 
Model 1 included age and sex as covariates. 
Model 2 was fully adjusted for covariates that displayed significant Bonferroni-corrected imbalance 
at baseline between patients with and those without MACE.  
Reclassification metrics (C-statistics and net reclassification improvement (NRI) were calculated as 
previously described.155  
Statistical significance was accepted at p <0.05.  
Microsoft Excel 2010 with embedded macros were used.  
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5. “Clock Rule” Analysis 
We have also re-analyze the CD14/CD16 plot of all the considered patients in a more objective 
way, using the “Clock Rule” analysis.110 
Monocytes were selected among all leukocytes on the FSC versus SSC plot and set on the CD16 
versus CD14 plot. From this plot, coordinates of each monocyte were exported using FlowJo® 
software, obtaining an X value corresponding to the FITC intensity and a Y value corresponding to 
the PE intensity.  
 
 
Fig. 12. Distribution of monocytes as a 90° angle; example of the clock rule. 
 
For each patient, firstly the double negative cells were gated to determine the coordinates of the 
point to be considered as the vertex (V) of the 90° angle [Fig. 12]. Secondly, for each monocyte to 
be analyzed, the angular coefficient has been calculated using the following formula: 
 
 
  
  
 
 
The value of the angle of each monocyte has been calculated using the arc-tangent function on the 
previously determined angular coefficient. As a result, lower angular values correspond to higher 
CD14 expression and lower CD16 expression, while higher angular value correspond to higher 
CD16 expression and lower CD 14 expression. Finally, the 90° angle was divided into 9 subsets of 
10° to quantify the distribution of monocytes on the curve. 
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RESULTS 
 
1. Patients’ characteristics 
The study included 227 patients. All patients had a high prevalence of cardiovascular risk factors, 
most showed a non optimal lipid profile and about the 50% had symptomatic or asymptomatic 
atherosclerotic cardiovascular disease at baseline [Tab. IV].156  
Demographics All patients Without MACE With MACE 
Number 227 221 26 
Age, years 61.0±0.7 60.4±0.7 66.0±1.6* 
Sex male, n (%) 139 (61.2) 122 (60.7) 17 (65.4) 
Body mass index, kg/m2 27.6±0.3 27.5 (0.3) 28.8 (0.7) 
Risk factors    
Active smoking, n (%) 49 (21.9) 42 (20.9) 7 (26.9) 
Hypertension, n (%) 146 (65.2) 125 (62.2) 21 (80.7) 
Obesity, n (%) 59 (26.0) 50 (24.9) 9 (34.6) 
Pre-diabetes, n (%) 38 (16.7) 37 (18.4) 1 (3.8) 
Type 2 diabetes, n (%) 100 (44.1) 83 (41.3) 17 (65.4) 
Non-optimal lipid profile, n (%) 165 (72.7) 146 (72.6) 19 (73.1) 
Laboratory exams    
Fasting plasma glucose, mg/dl (mmol/l) 100.5±1.6 
(5.6±0.1) 
100.3±1.6 
(5.6±0.1) 
106.3±6.4 
(5.9±0.4) 
Total cholesterol, mg/dl (mmol/l) 201.7±5.0 
(5.2±0.1) 
203.6±5.3 
(5.2±0.1) 
187.3±14.9 
(4.8±0.4) 
HDL cholesterol, mg/dl (mmol/l) 52.0±1.1 
(1.33±0.03) 
53.3±1.2 
(1.37±0.03) 
42.4±1.8* 
(1.09±0.05) 
LDL cholesterol, mg/dl (mmol/l) 125.2±4.6 
(3.2±0.1) 
125.8±4.9 
(3.2±0.1) 
120.1±14.0 
(3.1±0.4) 
Triglycerides, mg/dl (mmol/l) 131.0±7.3 
(1.5±0.1) 
129.3±8.1 
(1.5±0.1) 
143.8±13.8 
(1.6±0.2) 
eGFR, ml/min/1.73 m2 83.2±2.4 85.7±2.5 69.2±6.4* 
CKD, n (% of total) 28 (12.3) 21 (10.4) 7 (26.9) 
Cardiovascular disease    
Coronary artery disease, n (%) 56 (24.7) 41 (20.4) 15 (57.7)* 
Peripheral arterial disease, n (%) 15 (6.6) 8 (4.0) 7 (26.7)* 
Cerebrovascular disease, n (%) 42 (18.5) 35 (17.4) 7 (26.9) 
Atherosclerotic CVD, n (%) 112 (49.3) 94 (46.7) 18 (69.3) 
Medications    
ACE inhibitors / ARBs, n (%) 111 (42.9) 91 (45.3) 17 (65.4) 
Other anti-hypertensive agents, n (%) 68 (26.3) 54 (26.9) 11 (42.3) 
Anti-platelet agents, n (%) 85 (32.8) 67 (33.3) 16 (61.5) 
Statins, n (%) 178 (68.7) 146 (72.6) 23 (88.4) 
Glucose-lowering medications, n (%) 106 (46.6) 91 (45.2) 15 (57.7) 
Insulin, n (%) 36 (15.9) 27 (13.4) 9 (34.6) 
Tab. IV. Patients’ clinical characteristics. Comparison of patients without and with MACE after Bonferroni correction. 
Data are presented as mean ± standard error or as number or percentage. (*value significantly different in the 
comparison).156 
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2. Identifycation of monocyte subtypes at baseline 
We determined the frequency of the various subpopulations (mean ± standard error) using 
polychromatic flow cytometry in the patients’ blood samples collected at baseline. 
According to the traditional gating strategy we first performed a stringent monocytic 
“morphological gate” in the SSC-A versus FSC-A plot, then based on the combination of the 
CD14 and CD16 expression intensity have been described and characterized the discrete 
subpopulations of monocytes in the plot CD14 versus CD16 [Fig.13]. 
 
Fig. 13. Our gating strategy for the definition of the monocyte subtypes. 
 
• Classical monocytes CD14high CD16dim/neg: 67,1±1,4%. 
The classical monocyte population was split in two because was always detected a bivariate 
distribution of the CD16 expression on CD14high monocytes with various predominance of the two. 
A) Classical monocytes CD14++CD16neg:  28.1±1.6% [Fig.14 Example1]. 
B) Classical monocytes CD14++ CD16dim: 39.1± 1.5% [Fig. 14 Example2]. 
 
Fig. 14. CD14 versus CD16 plot and distribution of the classical population CD16neg (A) and CD16dim (B). 
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• Intermediate monocytes CD14++ CD16+: 13.7±1.3%. 
• Non-classical monocytes (CD14+ CD16+): 4.5±0.2%.  
• Two CD14neg cell subpopulations were identified:  
1) CD14neg CD16pos  subpopulation: 2.6 ± 0.1%; 
2) CD14neg CD16neg subpopulation: 7.1 ± 0.4% of total monocytes. 
To determine the nature of these two subpopulations, an immunophenotipic flow cytometric 
analysis was performed using various surface markers: most of these cells resulted negative 
for CD3 (T lymphocyte marker), CD19 (B lymphocyte marker), CD56 (NK cell marker), 
CD10 (granulocyte marker), but positive for CD33 (myeloid line marker) [Fig. 15]. 
 
 
Fig. 15. Plots describing the phenotype of the two subpopulation of monocytes CD14neg respectively CD16+ and 
CD16neg. 
 
These CD14neg subpopulation aren’t routinely considered so we did not further analyze them.156 
When summing the frequencies of the different subpopulations you don’t reach a 100% of 
monocytes because we did not include monocytes CD14neg in our analysis.  Compared to the 
literature, our data show higher level of intermediate monocytes and lower of non-classical ones 
[Tab. II]. 
In addition to the absolute number and the percentage frequency, we recorded also the mean 
fluorescence intensity (MFI) of CD14 and CD16. 
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3. Monocyte subsets and traditional cardiovascular risk factors  
All these information have been studied in relation to the cardiovascular risk factors considered in 
our research (type 2 diabetes, hypertension, active smoking, non-optimal lipid profile, obesity), and 
in relation to age (<or> age 65) and sex [Tab. V].  
51 
51 
 
  Age Sex Type 2 diabetes Hypertension Smoke Lipid profile Obesity 
  <65 years ≥65 years Females Males No Yes No Yes No Yes No Yes No Yes 
Number 136 91 88 139 127 100 79 146 178 49 165 62 168 59 
WBC, 103 / ml 7.55±0.22 7.68±0.27 7.40±0.26 7.72±0.22 7.74±0.22 7.43±0.26 7.49±0.28 7.66±0.22 7.60±0.20 7.59±0.36 7.74±0.19 7.17±0.35 7.48±0.19 7.96±0.36 
Granulocytes, % 57.2±0.7 54.8±0.9* 56.2±0.9 56.1±0.7 56.8±0.8 55.6±0.8 58.2±1.0 55.1±0.7* 56.4±0.6 55.6±1.1 56.6±0.6 55.3±1.1 55.8±0.7 57.6±1.0 
103/ml 4.34±0.14 4.21±0.16 4.17±0.16 4.34±0.14 4.41±0.14 4.14±0.16 4.34±0.17 4.25±0.14 4.29±0.12 4.25±0.22 4.38±0.12 3.99±0.22 4.18±0.12 4.58±0.21 
Lymphocytes, % 33.2±0.7 36.3±1.0* 34.3±1.0 34.7±0.8 33.8±0.8 35.4±0.9 32.2±1.1 35.7±0.7* 34.3±0.7 34.9±1.2 34.2±0.7 35.4±1.3 35.0±0.7 33.1±1.1 
103/ml 2.49±2.79 2.79±0.12* 2.54±2.66 2.66±0.09 2.61±2.62 2.62±0.11 2.43±2.71 2.71±0.09 2.61±2.62 2.62±0.15 2.65±2.50 2.50±0.14 2.60±2.64 2.64±0.15 
Monocytes, % 9.6±0.3 8.9±0.3 9.4±0.4 9.2±0.3 9.5±0.3 9.1±0.3 9.6±0.4 9.2±0.3 9.3±0.3 9.4±0.5 9.2±0.3 9.4±0.4 9.3±0.3 9.3±0.4 
103/ml 0.72±0.03 0.68±0.04 0.69±0.03 0.71±0.03 0.72±0.03 0.68±0.04 0.72±0.04 0.70±0.03 0.70±0.03 0.71±0.05 0.71±0.03 0.67±0.05 0.69±0.03 0.74±0.04 
Classical CD16neg                             
103/ml 0.21±0.02 0.17±0.02 0.24±0.03 0.17±0.02* 0.22±0.02 0.17±0.02 0.20±0.02 0.20±0.02 0.19±0.02 0.22±0.03 0.21±0.02 0.17±0.02 0.20±0.02 0.20±0.02 
% 29.9±2.1 25.4±2.3 32.8±2.6 24.6±1.9* 30.1±2.2 25.5±2.2 27.6±2.7 27.7±1.9 26.1±1.7 33.1±3.9 28.6±1.9 26.4±3.0 28.5±1.9 26.8±2.8 
CD14 MFI 11701±665 11782±730 11070±746 12226±655 10985±701 12683±672 11508±919 11822±579 11806±581 11379±898 11693±611 11855±728 11231±555 13163±1037 
CD16 MFI 155±7 168±8 154±9 166±7 121±6 210±6# 145±10 171±6* 158±6 175±10 155±6 176±10 152±6 184±10* 
Classical CD16dim                             
103/ml 0.26±0.02 0.29±0.02 0.24±0.02 0.29±0.02* 0.28±0.02 0.26±0.02 0.29±0.03 0.26±0.02 0.28±0.02 0.24±0.03 0.27±0.02 0.27±0.03 0.27±0.02 0.28±0.02 
% 36.9±2.0 42.4±2.3 36.1±2.3 41.3±1.9 38.9±2.1 39.3±2.1 39.3±2.5 39.4±1.9 40.6±1.6 34.9±3.5 38.8±1.7 39.8±2.8 39.1±1.8 39.0±2.6 
CD14 MFI 12237±683 12105±757 11524±726 12675±694 11484±713 13073±708 11839±894 12343±621 12208±593 12020±987 12136±630 12332±746 11580±554 13905±1133* 
CD16 MFI 2075±145 2071±126 2140±197 2042±106 1705±125 2541±151# 2238±193 2008±116 2052±113 2216±227 2051±121 2142±172 2042±121 2163±172 
Intermediate                             
/ml 107.38±17.0 88.69±14.52 86.1±18.6 109.5±15.2 87.6±14.6 115.5±19.1 84.00±17.39 110.2±15.64 89.4±11.07 142.77±36.8 101.0±14.25 96.46±19.3 93.2±12.82 118.9±26.54 
% 14.0±1.7 13.2±2.1 12.0±2.0 14.9±1.8 12.1±1.7 15.7±2.0 12.1±2.0 14.8±1.8 13.1±1.4 16.6±3.6 13.5±1.5 14.2±2.6 13.6±1.6 13.9±2.3 
CD14 MFI 11861±673 13041±1352 12618±1428 12222±626 11155±709 13830±1228* 11692±934 12680±916 12482±837 11815±844 12480±862 11886±748 11288±553 15312±2028 
CD16 MFI 9243±691 8923±529 9452±966 8950±444 7270±555 11457±720# 9307±843 9133±561 9057±550 9682±848 8967±559 9564±797 8959±577 9558±702 
Non-classical                             
/ml 33.38±2.28 30.75±2.25 32.11±2.63 32.57±2.10 33.67±2.24 30.62±2.38 36.71±3.23 30.15±1.84 34.11±1.91 26.46±3.15 33.40±1.98 29.04±2.66 31.20±1.90 35.55±3.17 
% 4.6±0.2 4.5±0.3 4.6±0.3 4.5±0.2 4.6±0.2 4.5±0.2 5.0±0.3 4.3±0.2* 4.8±0.2 3.6±0.3# 4.6±0.2 4.5±0.3 4.4±0.2 4.8±0.3 
CD14 MFI 1501±85 1616±236 1413±104 1642±164 1400±88 1733±215 1340±105 1660±156 1534±136 1603±108 1598±140 1391±82 1560±141 1511±97 
CD16 MFI 15161±1213 15127±981 15680±1673 14893±828 11694±999 19533±1251# 14563±1416 15665±1030 15017±996 16225±1351 14838±990 16092±1432 14723±1000 16356±1401 
Tab. V. Leukocyte counts (absolute and relative) and characterization of monocyte cells, in particular frequency (absolute and relative) and CD14 and CD16 MFI, in relation to age, sex and the 
presence of type 2 diabetes, hypertension, smoking, dyslipidemia and obesity. * Indicates a significant change in group comparison with p < 0.05; # indicates a significant difference after 
Bonferroni correction for multiple tests. 
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We first examined monocyte subsets in relation to the traditional cardiovascular risk factors, such as 
age, sex, type 2 diabetes, hypertension, active smoking, dyslipidemia and obesity. 
Comparing the different groups of patients, there were no significant differences in the 
subpopulations of monocytes associated with obesity, type 2 diabetes and lipid profile. 
In men versus women, we detected a reduction in the frequency of classical monocytes CD16neg and 
an increase in the frequency of classical monocytes CD16dim. 
In hypertensive patients (compared to those without hypertension) an increased in CD16 MFI on 
CD16neg and a reduction of non-classical monocytes was found. However, these variations are not 
significant after applying the Bonferroni correction for multiple tests. 
Instead, in smokers (compared to non-smokers), there was a robust decrease in non-classical 
monocytes (3.6 ± 0.3% vs. 4.8 ± 0.2%), which remained significant also after the correction for 
multiple tests. 
None of the examined risk factors was associated with changes in total white blood cell count and 
frequency of monocytes. 
 
Then, by analyzing the CD14 and CD16 MFI in each monocyte subpopulations, patients with type 2 
diabetes showed a strong and consistent up-regulation of CD16 compared to those without type 2 
diabetes [Fig. 16]: 
• 210 ± 6 vs 121 ± 6 on classical CD16neg; 
• 2541 ± 151 vs 1705  ± 125 on classical CD16dim; 
• 11457 ± 720 vs 7270 ± 555 on intermediate;  
• 19533 ± 1251 vs 11694 ± 999 on non-classical; 
despite we didn't observe significant changes in the frequency of every subsets. 
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Fig. 16. The plot shows the variations (and their respective error bars) of CD16 MFI (indicated with #) detected in 
patients with type 2 diabetes (in black) compared to non-diabetic patients (in red) in the four monocytic subpopulations 
considered in the patients of the study (in transparency the subpopulations CD14neg CD16neg and CD14neg CD16+  not 
further investigated). The histograms around show the average percentages of the monocytic subpopulations of diabetic 
patients (in black) and non-diabetics (in red), which show no significant differences. 
 
In hypertensive patients, an increase of CD16 MFI was noted in classical monocytes CD16neg, while 
in obese subjects an increase of MFI CD16 in classical CD16neg and an increase of CD14 MFI in 
classical CD16dim was observed. 
However, all these variations are not significant after the correction for multiple tests. 
No variation of the monocytic subpopulations related to age and the non-optimal lipid profile has 
emerged. 
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4. Monocyte subsets and prevalent cardiovascular disease 
Then patients were divided according to the presence of CAD at baseline [Tab.VI]. 
 
 Prevalent CAD 
 No Yes 
Number 171 56 
WBC, 103 / ml 7.68±0.22 7.51±0.33 
Granulocytes, % 56.3±0.7 55.0±1.1 
103/ml 4.34±0.14 4.15±0.20 
Lymphocytes, % 34.5±0.8 35.6±1.2 
103/ml 2.64±2.67 2.67±0.15 
Monocytes, % 9.2±0.3 9.4±0.4 
103/ml 0.71±0.03 0.69±0.04 
Classical CD16neg   
103/ml 0.20±0.02 0.18±0.03 
% 29.7±2.1 25.2±3.0 
CD14 MFI 11683±644 11199±894 
CD16 MFI 140±7 195±9# 
Classical CD16dim   
103/ml 0.28±0.02 0.27±0.03 
% 38.9±1.9 40.9±3.4 
CD14 MFI 12105±664 11914±1019 
CD16 MFI 1765±113 2039±140 
Intermediate   
/ml 75.42±11.37 157.6±32.6* 
% 10.1±1.3 20.9±3.7# 
CD14 MFI 12251±1014 11997±845 
CD16 MFI 7493±499 9784±618* 
Non-classical   
/ml 33.29±2.11 26.25±2.83 
% 4.6±0.2 3.7±0.3* 
CD14 MFI 1260±57 2086±372# 
CD16 MFI 12026±897 17202±1008# 
 
Tab. VI. White blood cells (WBC), relative and absolute counts of leukocytes, frequency and CD14/CD16 mean 
fluorescence intensity for each monocyte subsets in patients with and without baseline coronary artery disease 
(CAD).*p<0.05; #significant after Bonferroni correction. 
 
In patients with prevalence of CAD, compared to subjects without, a significant increase in the 
frequency of intermediate monocytes emerged (20.9 ± 3.7% versus 10.1 ± 1.3%). 
We analyzed the mean fluorescence intensity of CD14 and CD16: there was an increase in 
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CD16MFI in classical monocytes CD16neg (195 ± 9 versus 140 ± 7); an increase of CD14 MFI 
(2086 ± 372 versus 1260 ± 57) and CD16 MFI (17202 ± 1008 versus 12026 ± 897) on non-
classical. These increases remained significant after the correction for multiple tests. 
There is also a significant reduction in non-classical monocytes (3.7 ± 0.3% versus 4.6 ± 0.2%, with 
p < 0.01), but this variation was not significant after the correction for multiple tests. Similarly, the 
increase of CD16 MFI on intermediate monocytes also loses its meaning (9784 ± 618 versus 7493 ± 
499) [Fig. 17]. 
 
 
 
 
Fig. 17. The plot shows the significant variations (and their respective error bars) of CD16MFI (indicated with #), 
highlighted at the level of classical monocytes CD16neg, and CD14 (indicated with *) at the level of non-classical 
monocytes, detected in CAD patients (in black) compared to patients without CAD (in red) (in transparency the 
monocytic subpopulations CD14-CD16- and CD14-CD16+ not further investigated in this study). 
The histograms represent the average percentage frequencies of monocytic subpopulations in CAD patients (in black) 
and in non-CAD patients (in red). The * in the histogram indicates a significant difference (p < 0.05). 
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5. Monocytes subsets and cardiovascular outcomes 
Patients were followed-up for a median of 4.2 (3.1-4.8) years. During the follow up: 
• 7 patients died: 4 for cardiovascular death and 3 for cancer related causes; 
• 22 patients had cardiovascular events of which: 9 AMI, 1 stroke, 5 hospitalizations for unstable 
angina, 7 hospitalizations for heart failure. Not considering the 3 deaths for non-cardiovascular 
reasons.  
The combined MACE endpoint (composed by cardiovascular events and cardiovascular death) 
occurred in 26 patients of the 227 (equal to an annual rate 2.9%). 
 Incident MACE 
 No Yes 
Number 201 26 
WBC, 103 / ml 7.60±0.18 7.59±0.52 
Granulocytes, % 56.5±0.6 54.1±1.8 
103/ml 4.31±0.11 4.13±0.32 
Lymphocytes, % 34.2±0.6 36.7±1.9 
103/ml 2.59±2.77 2.77±0.22 
Monocytes, % 9.3±0.2 9.2±0.7 
103/ml 0.70±0.02 0.69±0.07 
Classical CD16neg   
103/ml 0.20±0.02 0.17±0.04 
% 28.4±1.7 25.5±4.2 
CD14 MFI 11652±528 12364±1404 
CD16 MFI 154±6 209±15# 
Classical CD16dim   
103/ml 0.27±0.02 0.23±0.04 
% 39.6±1.6 35.4±4.2 
CD14 MFI 12094±539 12885±1551 
CD16 MFI 2037±108 2356±265 
Intermediate   
/ml 90.95±11.66 169.0±47.2* 
% 12.6±1.3 21.8±4.6* 
CD14 MFI 12213±733 13269±1643 
CD16 MFI 8837±488 11262±1433 
Non-classical   
/ml 32.58±1.77 30.38±4.00 
% 4.6±0.2 4.5±0.4 
CD14 MFI 1419±56 2540±816# 
 
Tab. VII. White blood cells (WBC), relative and absolute counts of leukocyte, frequency and CD14/CD16 mean 
fluorescence intensity (MFI) for each monocyte subsets are presented in patients with or without incident MACE. 
*p<0.05; #significant after Bonferroni correction. 
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The most significant clinical observations in patients with MACE during follow-up, compared to 
those without, after adjusting for multiple testing, are summarized in Tab. VII: 
-  were significantly older (66.0 ± 1.6 vs 60.4 ± 0.7); 
- had lower level of HDL-cholesterol (mg/dl) (42.4 ± 1.8 vs 53.3 ± 1.2); 
-  had a minor EGFR (ml/min/1.73 m2) (69.2 ± 6.4 vs at 85.7 ± 2.5); 
- had a higher prevalence of coronary artery disease (57.7% vs 20.4%) and peripheral arterial 
disease (26.7% vs 4.0%). 
 
Similar monocytic alterations to those observed in CAD patients have occurred in patients with 
MACE during follow-up, compared to those without [Tab.VII].  
They displayed a higher baseline frequency of intermediate monocytes (21.8 ± 4.6% versus 12.6 ± 
1.3%, with p < 0,026, but not significant after the correction for multiple tests).  
According to the analysis of monocytes distribution, patients with incident MACE compared to 
those without showed a shift of non-classicals towards intermediates, as evidenced by the increase 
in both CD16 MFI (20569 ± 2804 versus 14446 ± 848, with P < 0,017) and CD14 MFI (2539 ± 815 
versus 1418 ± 56; p < 0.0001) on non-classicals. 
A significant shift of CD14++ CD16neg towards CD14++ CD16dim monocytes was noted based on 
CD16 MFI (208 ± 15 versus 154 ± 5; p = 0.001) [Fig. 18]. 
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Fig. 18. The plot represents the variations (and their respective error bars) of CD16 MFI (indicated with #) in the 
classical monocytes CD16neg and the increase of CD14 MFI (indicated with*) and CD16 MFI (indicated with #) on 
non-classical monocytes, in patients with MACE (in black) compared to patients without MACE (in red) during follow-
up (in transparency the monocytic populations CD14-CD16- and CD14-CD16+ not further investigated in this study). 
Histograms represent the average percentage frequencies of the monocyte subpopulations in patients with MACE (in 
black) compared to those without (in red). The * in the histogram of intermediate monocytes shows the difference in the 
two groups (p < 0.05). 
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6. Monocyte subpopulations and mace prediction 
The Cox proportional hazard regression model was applied to assess whether the significant 
alterations of the monocytic cells highlighted in patients with MACE (Table III), i.e. the increase in 
the percentage frequency of intermediates, the increase in CD14 MFI and CD16 MFI on non-
classical, and the increase in CD16 MFI on classical CD16neg monocytes, can independently predict 
the incidence of MACE. 
In the first regression model (Model 1) the adjustment was made by age and sex; in the second 
model (Model 2) in addition to age and sex, adjustment has been made for different clinical 
characteristics significantly at baseline between patients who had MACE compared to those who 
hadn't MACE: Cholesterol HDL, chronic renal failure, coronary artery disease [Tab VIII]. 
 
Variables Model 1 Model 2 
 HR for 1 SD p HR for 1 SD p 
Intermediate monocytes, % 1.35 
 (1.06-1.71) 
0.014 1.19  
(0.93-1.51) 
0.167 
Non-classical CD14 MFI 1.18  
(1.04-1.35) 
0.011 1.10  
(0.95-1.27) 
0.214 
Non-classical CD16 MFI 1.37  
(1.07-1.74) 
0.011 1.23  
(0.93-1.64) 
0.142 
CD14++CD16neg CD16 MFI 1.87  
(1.30-2.69) 
0.001 1.63  
(1.07-2.49) 
0.023 
 
 
Tab VIII. Analysis of survival free from MACE. Application of Cox regression model correction. Model 1 is adjusted 
by age and gender; Model 2 is adjusted by age, sex, HDL-cholesterol, chronic kidney failure, coronary artery disease, 
variables that were significantly different between patients with and without MACE during follow-up. 
 
In Model 1 all variables, intermediate monocytes, CD16 MFI on classical, CD16 and CD14 MFI on 
non-classical have been significantly predicting the incidence of MACE (p < 0.05 for each 
variable). 
However, in Model 2, only the CD16 MFI on classical monocytes CD16neg remained significantly 
associated with the incidence of MACE (p < 0.05), showing a 63% increased risk for one SD 
increased in CD16 MFI. 
 
 
 
60 
60 
 
The Kaplan Meier curves derived from Model 2 for CD16 MFI on classical monocytes, categorized 
as high or low based on the median value, shows that patients with higher CD16 MFI on classical 
CD16neg have less event-free survival [Fig. 19]. 
 
 
 
 
 
 
Fig. 19. Kaplan-Meier curve derived from Model 2 highlights lower events free-survival in patients with higher 
CD16MFI on classic CD16neg monocytes. The * indicates a significant difference between the two curves. The table 
below shows the number of patients at risk over time. For the reclassification criteria, the addition of the variable 
"CD16MFI in classical monocytes CD14++ CD16neg" in Model 2 led to a significant increase in C statistics and to a 
significantly increased NRI (34.4%, with p < 0.02), especially because it allows a better reclassification of patients 
without events. 
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7. Analysis according to the “Clock Rule”  
We have also re-analyze the CD14 versus CD16 plot of all the patients in a more objective way, 
using the “Clock Rule” analysis.110 
Monocytes were selected among all leukocytes on the FSC versus SSC plot, and set on the CD16 
versus CD14 plot. From this plot, coordinates of each monocyte were exported using FlowJo® 
software, obtaining an X value corresponding to the FITC intensity and a Y value corresponding to 
the PE intensity.  
For each patient, the double negative cells were first gated to determine the coordinates of the point 
to be considered as the vertex (V) of the 90° angle. Secondly, for each monocyte to be analyzed, the 
angular coefficient has been calculated.  
The value of the angle of each monocyte has been calculated using the arc-tangent function on the 
previously determined angular coefficient.  
As a result, lower angular values correspond to higher CD14 expression and lower CD16 
expression, while higher angular value correspond to higher CD16 expression and lower CD 14 
expression. Finally, the 90° angle was divided into 9 subsets of 10° to quantify the distribution of 
monocytes on the curve. 
 
First, monocyte distribution was examined in relation to the presence or absence of baseline CAD 
[Fig. 20]. 
 
 
Fig. 20. Figure Clock Rule analysis for monocytes distribution in patients with (green line) and without (red line) 
baseline CAD. * Significant difference between the two curves. 
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The only significant difference observed between these two groups was in the higher angular value 
part of the histogram, which correspond to an higher CD16 expression and a lower CD14 
expression, characteristic of the intermediate and non-classical populations. 
 
Instead, when comparing monocyte distribution of patients with and without MACE, no significant 
differences were noticed [Fig. 21]. 
 
 
 
Fig. 21. Clock Rule analysis for monocytes distribution in patients with (green line) and without (red line) MACE at 
follow-up. There isn't a significant difference between the two curves. 
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DISCUSSION AND CONCLUSIONS 
 
Previous studies of our research group on prediabetic, diabetic, and hypercolesterolemic patients did 
not show any significant effect of these traditional risk factors on the levels of traditional monocyte 
subsets.116,117,141 With the present work, we confirmed that cardiovascular risk factors caused 
marginal effects on the frequency of classical, intermediate and non-classical monocytes. The most 
important finding of this study was that, analyzing the monocyte positioning along the continuum of 
the CD14 versus CD16 plot, it is possible to provide incremental information on cardiovascular risk 
and outcomes over the traditional assessment of monocyte subsets.156 
During the course of disease, such as systemic inflammation104 and also following pharmacologic 
treatment may occur dynamic changes in monocyte subsets. For this reason, it can be useful for 
diagnosis and follow-up in human diseases to quantify these functionally different subsets in 
peripheral blood and a baseline assessment might be used as a predictive parameter or as a 
biomarker for future cardiovascular events.110 
 
Based on the recent kinetic work of Patel and colleagues, by in vivo labelling of human monocytes 
with deuterium, we can summarize the physiological cascade of monocyte subsets in the following 
way: monocytogenesis proceeds through the subsequent evolution of classical monocytes into 
intermediate and non-classical ones [Fig. 22].  
 
 
 
Fig. 22. Schematic representation of monocytes frequency in a healthy subject.110 
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After being released into the circulation, classical monocytes dead or migrate and leave the 
bloodstream, while a minority of them differentiate into intermediates within 3 days. Intermediates, 
instead, circulate for other 3 days before transiting to the non-classical phenotype. Finally, non-
classical have the longest lifespan (7 days), and they ultimately leave the bloodstream.104 
By analyzing monocyte position along their continuum in the CD16/CD14 plot, we provided 
incremental information on cardiovascular risk and outcomes, complementing the traditional 
assessment of monocyte subsets. In fact, patients with a condition of high cardiovascular risk are 
characterized by a shift of monocytes from classical to intermediates and a reduction of non-
classical ones.156 This kind of altered distribution be result of an enhanced differentiation of 
classical to intermediates, along with a reduced differentiation of intermediates into classical ones 
[Fig. 23]. 
 
 
Fig. 23. Schematic representation of changes in monocytes frequency in a patient with cardiovascular risk.110 
 
The meaning of the two additional small populations of monocytes CD14neg (CD14-CD16+ and 
CD14-CD16-) remains still unclear and needs further investigation;156 we suggested they should 
represent phenotypes in-transition towards DCs or “aged” cells. 
By scoring hundreds of plots, we observed that, differently from the traditional gating of monocyte 
subsets, the classical monocyte compartment, CD14high CD16-/low contained a bivariate distribution 
of CD16neg and CD16dim cells, with remarkable differences among patients. We thus speculated that 
significant heterogeneity within each monocyte subset may convey clinical information.156  
Regarding the monocyte population as a continuum of subsets103,123 we hypothesized that 
displacement of monocytes in the CD14 versus CD16 plot was better detectable by analyzing the 
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distribution, mean and standard deviation, of CD14 and CD16 fluorescence intensity rather than cell 
frequency in each discrete gate. For example, type 2 diabetic patients, despite having no changes in 
the monocyte subsets frequency, showed a consistent and highly significant shift of all subsets 
towards a higher CD16 expression.156 We speculated that a generalized induction of CD16 may be 
related to cardiovascular risk in diabetes, because CD16+ monocytes correlated with subclinical 
atherosclerosis in a large sample of healthy volunteers,101 while CD16 deletion in murine models 
shows a reduction in the atherosclerosis development.157 
Substantially, in patients with prevalent coronary artery disease, in addition to a doubled frequency 
of intermediate monocytes, the analysis of distribution revealed a shift of classical and non-classical 
towards intermediate monocytes. In CAD patients, an expansion of CD16pos monocytes has 
previously been noticed and is linked with levels of the pro-inflammatory cytokine TNF-α.136 
Previously there has been several efforts to describe monocyte heterogeneity in a simplified way 
compared to than the traditional subdivision,134 while the functional implications remained 
unknown. 
We carried out a longitudinal patient evaluation with a follow-up of 4 years to establish whether an 
irregular monocyte distribution was predictive of future cardiovascular disease. Patients who 
occurred a MACE compared to those who did not, had baseline alterations in monocytes similar to 
those of CAD patients, characterized by higher levels of intermediate monocytes and a shift of 
classical and non-classical monocytes toward intermediate ones.156 Because it was possible to 
confound the association with baseline CAD, a Multivariate Cox proportional hazard regression 
analyses has been used. In fully-adjusted models including baseline CAD, only higher CD16 
expression on classical monocytes remained significantly associated with incident MACE: showing 
a 63%. 
As already reported in literature, levels of either intermediate104,158 or classical149 monocytes 
predicted cardiovascular events. Our findings, by showing that distribution within specific 
monocyte subsets predict cardiovascular outcomes more than their frequencies, provide possible 
explanations for inconsistencies in our previous studies.156 
This study has some limitations. First, the relatively small number of patients who experienced 
MACE, despite a reasonably long period of follow-up.  
In addition, in this study monocytes were only defined based on CD14 and CD16 expression, while 
more antigenic specification has been recently performed to improve definition of monocyte 
phenotypes that may aid a better stratification of cardiovascular risk.78 It should also be noted that, 
besides antigenic definition, additional work is required to profile these subsets in terms of function 
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and gene expression.97,98 In fact, these subpopulations may be associated with differences in pro-
inflammatory gene expression as previously shown e.g. in CAD patients.136 
Finally, monocytes were only analyzed in the beginning of the study, while a time-course analysis 
may better clarify how stable are the baseline alterations observed and whether there are temporal 
trend preceding the MACE. 
 
Certainly, a polychromatic flow cytometry analysis has also some methodological limitations. First 
of all the lack of consensus in the monocyte subtypes phenotype. Scoring the literature there are a 
lot of different immune-phenotype panels used to identify the subpopulations of monocytes.  
In terms of technical performance, new consensus statements recommend the use of an additional 
pan-monocytic marker (such as CD86 or HLA-DR) but in this work we have only use the CD14 
and the CD16.76 The use these two markers alone might be limited by different gating strategies that 
may generate various phenotypic profile patterns.107 Discrimination among the monocyte 
subpopulations is subjective and depends on the operator: may be affected by the selection of 
different gate, for example “rectangular” versus “trapezoidal” or more sophisticated gates.159,160 
Scoring CD14 versus CD16 plots in the literature, sometimes it seems that CD14++ CD16low subsets 
may be part of CD14++ CD16+ subsets.110 It depends on how CD16 negativity is defined. However, 
showing the entire population as an ideally infinite number of monocyte subsets described by the 
expression of CD14 and CD16 on monocytes, we conclude that distribution of key markers within 
specific monocyte subsets predicts cardiovascular outcomes more than the frequency of monocyte 
subsets.156 
Another matter is providing percentages as opposed to absolute counts. Thus, also absolute counts 
of monocytes, neutrophils and lymphocytes based on white blood cell count may be useful in 
detecting significant differences in the monocyte population recorded at baseline. The confounding 
effects of an enhanced white blood cell count are often viewable in patients with high 
cardiovascular risk.161 Absolute counts would be more relevant unless it were found that one subset 
provides to high levels of a particular risk factor and other subsets to lower levels of the same risk 
factor. In this regard, the absolute count of intermediate monocytes predict cardiovascular events in 
patients with kidney disease patients.145,146 
On the other hand, during our research the use of the more objective “Clock Rule” analysis didn't 
show the expected prognostic information in term of cardiovascular risks and outcomes. A great 
amount of data were exported for this kind of analysis. The only significant difference observed was 
between the groups of patients with and without CAD only for the distribution of monocytes 
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displaying a higher CD16 expression and a lower CD14 expression, characteristic of the 
intermediate and non-classical populations. Instead, when comparing monocyte distribution of 
patients with and without MACE, no significant difference was observed. So, we can conclude that 
our first analysis based on CD14 and CD16 MFI provides a better prognostic information rather 
than the ‘Clock Rule” analysis. 
Our aim is not to propose a new way of monocytes analysis and this sophisticated flow cytometry 
approach should not be applied to define an individual patient's cardiovascular risk. On the other 
hand, our data straightforwardly demonstrate how the concept of monocyte continuum provides 
further information in cardiovascular disease and in the prediction of cardiovascular risk and should 
be used to study several pathological conditions in which monocytes are involved. 
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